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Abstract 
Andrographolide (AND), a bicyclic diterpenoid lactone, is one of the major 
components of the herb Andrographis Paniculata md has been shown to possess a wide 
range of pharmacological properties. The present study is to understand the biological 
activity of AND. In vitro study, treatments of HepG2, Clone 9 and WRL 68 cell lines 
with AND were performed in a time-course study. Results showed that AND inhibited 
the growth of the cell lines. Cell cycle analysis demonstrated that AND-treated HepG2 
cells were blocked in the G q - G i phase of cell cycle, and DNA fragmentation was 
observed. Micro array analysis indicated the changes in the gene expressions that are 
associated with cell cycle control and apoptosis. 
In vivo study of effects of AND on tumor development in the promotion and 
progression stages were investigated in a 28- and 56-week study, respectively using 
Spraque Dawley (SD) rats. Health conditions of the AND-treated group (lOmg/kg; once 
daily), positive control group (DEN-CCI4 treated) and negative control group were 
monitored. After treatment, AST and ALT assays were performed to study the effect of 
the active component on liver. Western blots were performed to detect the protein 
expressions of PCNA, Bax, Bcl-2, p21, Mdm2, total and wild-type p53. mRNA 
expression levels of p53 and Mdm2 were also investigated. Haemotoxylin and Eosin 
(H&E) staining and immunostaining of GST-P of the liver sections of rats were 
performed to study the responses of hepatocytes. 
The results showed that AST and ALT levels were reduced in the AND-treated 
group in both promotion and progression experiments. The protein expression of PCNA 
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was found to decrease, indicating a reduction of liver cell proliferation in the treatment 
group. Also, the over expression of wild-type p53 activated the expressions of Bax and 
p21 but inactivated the expression of Bcl-2. The regulator of p53, Mdm2, was also found 
to decrease. The overall regulation of these proteins showed the effects of AND on the 
apoptotic event in liver cells. At the transcriptional level, the mRNA expressions of p53 
and Mdm2 were also found to reduce with treatment of AND. The results demonstrated 
that the increase in total p53 protein was due to the increase in wild-type p53 in the 
AND-treated group. Histological examinations revealed that the basic hexagonal 
structure was restored and the immunostaining of the liver section showed reduction in 
GST-P foci after treatment with AND. These findings showed that AND has 
pharmacological activity in cancer cells. The over-expression of genes associated with 
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Introduction I -- Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC, also called hepatoma or liver cancer) is a primary 
malignancy that arises from hepatocytes, the major cell type of the liver. It is the fifth 
most common cancer and causes one million deaths annually worldwide (1). It is 
especially prevalent in parts of Asia (China, Hong Kong, Taiwan, Korea and Japan) and 
sub-Saharan Africa (Mozambique and South Africa). However, a recent study indicate 
that the frequency of HCC in the U.S. overall is rising as well (2). 
Risk factors 
HCC is considered a multistage disease whose occurrence is caused by the 
interaction between genetic and environmental factors. Chronic hepatitis virus (HBV and 
HCV) infections, dietary aflatoxin B1 (AFBl) ingestion, diabetes, chronic alcohol abuse 
and cirrhosis associated with genetic liver diseases are the most prevalent risk factors for 
HCC overall (3). Among them, chronic infection with HBV or HCV is the most frequent 
underlying cause of HCC. Recent study revealed that HBV infection accounts for as much 
as 80% of the tumors in HCC in developing countries (4). Besides that, a higher incidence 
of HCC has been shown in certain genetic defects such as porphyria, a-1 antitrypsin 
deficiency, and Wilson disease (5). Certain carcinogenic chemicals, including arsenic and 
anabolic steroids are also identified as risk factors of liver cancer. 
Usually, HCC arises from an adenomatous hyperplasia in an already diseased liver 
and progresses from a well-differentiated stage to less-differentiated forms (6). Ordinary 
HCCs formed by progression show highly increased cellular proliferation, 
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neovascularization, production of basic fibroblast growth factor, and aneuploidy in some 
tumors (7). Corresponding to its malignant progression, HCCs also show loss of 
heterozygosity for multiple chromosomes (8). 
Stages in chemical carcinogenesis 
The molecular mechanisms behind HCC malignancies are complex. It has been 
proposed that inflammation of the liver may lead to aberrant cell death or the deviant 
stimulation of mitosis, resulting in an accumulation of molecular and cellular events 
necessary for oncogenic hepatocyte cell transformation (9). The process of 
hepatocarcinogenesis can be distinguished into three different stages: initiation, promotion 
and progression. 
1. Initiation 
The first stage in carcinogenesis is tumor initiation which results from irreversible 
genetic change. For mutations to accumulate, they must arise in cells that proliferate and 
survive the lifetime of the organism. A chemical carcinogen causes a genetic alteration or 
error by the modification of the molecular structure of DNA that leads to a mutation 
during DNA synthesis. Most often, DNA mutation is brought about by formation of an 
adduct between the chemical carcinogen or one of its functional groups and a nucleotide in 
DNA. There is a positive correlation between the number of carcinogen-DNA adducts 
and the number of tumors that develop in animal models. Therefore, tumors can hardly be 
detected in tissues that do not form these carcinogen-DNA adducts. The formation of 
these adducts is considered to be a necessary, but not sufficient, prerequisite for tumor 
initiation (10). The cellular responses to DNA adducts may result in repair of the damage, 
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cell death by apoptosis, or continued cell proliferation. However, if these DNA errors are 
not repaired before cell replication, cells with modified DNA sequence will result. 
Histological sections of grossly normal liver from an animal treated with a 
carcinogen just a few weeks earlier revealed the presence of discrete areas of aberrant 
enzyme activity (11). These 'islands' are generally referred to as enzyme-altered foci 
(EAF) which display many phenotypic alterations such as increase in glucose-6-phosphate 
dehydrogenase. These EAF are believed to be the earliest identifiable progeny of initiated 
cells that have the potential to progress to hepatocellular carcinomas (12). 
Carcinogenic initiators can be divided into two types: direct acting and indirect 
acting initiators. Direct acting initiators are often alkylating or acetylating agents such as 
cyclophosphamide and aflatoxin B1 which have weak initiator activity. Indirect initiators 
are also called "procarcinogens" and they are the most common type of initiators. These 
initiators require metabolic conversion through the P450 systems to exert their toxic 
effects. Examples include polycyclic aromatic hydrocarbons (PAH) like epoxides found in 
smoked foods and nitrosamines like diethylnitrosamine (DEN) in pickled foods. 
2. Promotion 
The second stage in carcinogenesis is promotion which comprises a reversible 
process involving multiple applications of a promoting agent. This agent induces cellular 
proliferation and selective clonal expansion of the preneoplastic cells. Since the 
accumulation rate of mutations is proportional to the rate of cell division, clonal expansion 
of initiated cells produces a larger population of cells that are at risk of further genetic 
changes and malignant conversion. Tumor promoters generally are non-mutagenic and 
non-carcinogenic alone. These agents can mediate their biological effects without further 
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metabolic transformation. They are characterized by their ability to reduce the latency 
period for tumor formation after exposure of a tissue to a tumor initiator or to increase the 
frequency of tumors formed in that tissue. Moreover, they can induce the formation of a 
tumor in conjunction with a dose of an initiation that is too low to be carcinogenic alone 
(12). 
Many tumor promoters can be found in the environment. An example is croton oil 
which is isolated from Croton tiglium seeds. It has been widely used as a promoter in skin 
carcinogenesis. Its most potent constituent, 12-tetradecanoylphorbol-13-acetate, activates 
protein kinase C which in turn causes phosphorylation of many substances and stimulates 
a cascade of epigenetic changes that can lead to cell growth (13). Another example will be 
carbon tetrachloride, CCI4, a solvent that was used in the past as cleaning fluid and 
industrially in the synthesis of refrigeration fluid and propellants for aerosol cans (14). The 
major effect of exposure to CCI4 in humans and animals is hepatotoxicity, which is 
detectable by biochemical alterations such as elevated levels in enzymatic activities in the 
liver or histological examination such as destruction of intracellular organelles and 
necrosis of central hepatocytes. The toxic effects of CCI4 are related to its metabolism by 
cytochrome P-450 oxygenases, CYP 2E1. This enzyme metabolizes CCI4 and generates a 
reactive metabolite called trimethyl chloride radial. This reactive radial covalently binds 
to DNA in the liver and causes lipid peroxidation products in animals by intraperitoneal 
injection. In addition, there is evidence that CCI4 can also cause cancer by a nongenotoxic 
mechanism involving cellular regeneration. The increase in cell proliferation could result 
in either the replication of unrepaired DNA damage or the induction of more errors during 
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the replication process. Both of which can produce mutations that result in promoted 
growth of initiated preneoplastic cells. 
The contribution of tumor promotion to the process of carcinogenesis is the 
expansion of a population of initiated cells. Repeated administration of a promoter may 
transform a preneoplastic cell into one that expresses the malignant phenotype. 
Conversion of a fraction of these cells to malignancy could be accelerated with the 
increase in the rate of cell division, a process that may mediate the activation of proto-
oncogenes and inactivation of tumor-suppressor genes (15). 
3. Progression 
This stage of hepatocarcinogenesis comprises the expression of the malignant 
phenotype and the tendency of already malignant cells to acquire more aggressive 
characteristics with time, one of which is the metastasis of neoplastic cells. In this process, 
there are secretions of proteases from malignant cells that allow invasion beyond the EAF. 
The most prominent characteristic of malignant phenotype is the propensity for genomic 
instability and uncontrolled cell growth (16). This process again involves the activation of 
proto-oncogenes and the functional loss of tumor-suppressor genes to cause further genetic 
changes. The mutated or over-expressed products of the oncogenes stimulate mitosis even 
though normal growth factors like PDGF (platelet-derived growth factor) are absent. 
Tumor-suppressor genes are those that inhibit mitosis. Mutated or deleted tumor 
suppressor genes such as p53 will result in uncontrollable cell division. There are also 
genes that enable tumor cells to separate from the primary tumor and migrate to other parts 
of the body. There can be mutations in the metastasis genes whose products normally 
keep cells adhering to one another. An example is the E-cadherin genes that hold 
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epithelial cells together. Mutations can also occur in genes whose products normally keep 
the cells adhering to their substrate, such as the integrin genes. Elevated expression of the 
genes that encode proteases can break down the extracellular. material which holds the 
cells in place (17). 
Treatment of hepatocarcinoma 
The various treatment options are dictated by the stage of HCC and also the overall 
condition of the patient. Most common therapies for HCC include chemotherapy, trans-
arterial chemoembolization (TACE), radiofrequency ablation (RFA), percutaneous ethanol 
injection, liver resection and liver transplantation. 
1. Chemotherapy — hepatic arterial infusion (HAI) 
Chemotherapy for the treatment of hepatic metastases has evolved from a 
systemic-only regimen to a liver-directed regimen. Since HCC tumor cells get blood 
exclusively from the hepatic artery, chemotherapy agents are specifically delivered 
through an implanted subcutaneous constant-flow pump directly to the tumor. At present, 
the most commonly infused chemotherapy agent in the treatment of hepatic metastases is 
fluorodeoxyuridine (FUDR). It is a pyrimidine antagonist related to 5-fluorouracil (5-FU) 
that has shown activity against hepatic colorectal metastases (18). 
The rationale of HAI chemotherapy is based on three concepts. First, hepatic 
metastases greater than 3 mm in size derive their blood supply from the hepatic artery and 
not the portal vein (19). Second, a 4-fold increase in the concentration of 
chemo therapeutic agent can be achieved in the liver when drug is delivered through the 
hepatic artery instead of being systematically infused (20). Third, certain chemotherapy 
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agents such as FUDR can be completely extracted during the first pass through the liver, 
allowing for large doses to be given via the hepatic artery with minimal systemic effects 
(19). However, there are also some common complications related to this treatment. 
Chemical cholecystitis and peptic ulceration or perforation have been reported due to 
malperfusion. In some cases, sclerosing cholangitis and cirrhosis have been developed 
with the FUDR-based chemotherapy. Nausea, vomiting and diarrhea are the common 
complications of floxuridine- or 5-FU-based HAI chemotherapy (21). 
2. Trans-arterial chemoembolization (TACE) 
This technique is the standard approach in selected patients with unresectable HCC. 
It also takes advantage of the fact that HCC is a very vascular tumor and gets its blood 
supply from branches of hepatic artery. This procedure is similar to intra-arterial infusion 
of chemotherapy. First, a very high concentration of chemotherapy is delivered directly 
into the tumor, without exposing the drug systemically. Second, an additional step of 
blocking (embolizing) the blood flow to the tumor deprives it of oxygen and nutrients, and 
traps the drug at the tumor site to enable them to be more effective. The embolization is 
achieved with different types of compounds such as gelfoam or gelatin sponge. Therefore, 
TACE has the advantages of exposing the tumor to high concentrations of chemotherapy 
and confining the agents locally. 
TACE has been shown to be effective in decreasing the size of the tumor in two-
thirds of HCC treated. It can also be used in combination with other therapies such as 
radiation and tumor ablation. However, there is always a risk that embolization material 
can lodge in the wrong place and deprive normal tissue of its blood supply. Further, they 
can be used only in patients with unresectable intermediate HCC and relatively preserved 
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liver function because the procedure can lead to liver failure and eventually death in 
individuals with poor liver function. 
3. Radiofrequency ablation (RFA) 
Radiofrequency ablation is being increasingly performed worldwide. Currently, it 
is predominantly performed for treatment of hepatic tumors that are not amenable to 
resection. The most common tumors treated by RFA are HCC and colorectal metastases. 
Results of long-term survival rates of individuals treated by this procedure have recently 
become available. These studies show that the most important determinant for achieving 
complete ablation is the size of the tumor. In general, technically successful ablation is 
possible in 90% of tumors that are less than 2.5 cm in diameter, in approximately 70% to 
90% of tumors with 2.5- to 3.5-cm diameter, in 50% to 70% of tumors with 3.5 to 5.0 cm 
in diameter, and less than 50% of tumors with greater than 5.0 cm in diameter (22-24). 
Tumor type is also reported to affect the outcome with better success in treating HCC. 
Studies have also shown that tumor histology directly affects the success rate with well-
differentiated HCC having better results of ablation than infiltrating lesions (22, 24). 
This procedure is performed laparoscopically (through small holes in the abdomen) 
or during open exploration of the abdomen. In some instances, the procedure can be done 
without opening the abdomen by using ultrasound for visual guidance. In RFA, heat is 
generated locally by a high frequency, alternating current that flows from the electrodes. A 
probe is inserted into the center of the tumor and the non-insulated electrodes, which are 
shaped like prongs，are projected into the tumor. The local heat generated melts the tissue 
(coagulative necrosis) that is adjacent to the probe. The probe is left in place for about 10 
to 15 minutes. The whole procedure is monitored visually by ultrasound scanning. 
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4. Percutaneous ethanol injection (PEI) 
Pure alcohol is injected into the tumor through a very thin needle with the help of 
ultrasound or CT visual guidance. Alcohol induces tumor destruction by dehydrating 
tumor cells and thereby denaturing the structure of cellular proteins. It may take up to five 
or six sessions of injections to completely destroy the tumor. The ideal patient for alcohol 
injection should have fewer than three HCC tumors, each of which should be less than 3 
cm in diameter, should have distinct margins and fibrous encapsulation and should not be 
near the surface of the liver. Moreover, patients with HCC undergoing PEI should have 
no signs of chronic liver failure such as jaundice (25). 
The most common side effect of alcohol injection is leakage of alcohol onto the 
surface of the liver and into the abdominal cavity, thereby causing pain and fever. It is 
important that the location of the tumor relative to the adjacent blood vessels and bile 
ducts is clearly identified. The reason for that is to avoid injuring them during the 
procedure and causing bleeding, bile duct inflammation, or bile leakage (25). 
5. Liver resection 
The goal of liver resection is to completely remove the tumor and the appropriate 
surrounding liver tissue without leaving any tumor behind. This option is limited to 
patients with one or two small (3 cm or less) tumors and excellent liver function, ideally 
without associated cirrhosis. When a portion of a normal liver is removed, the remaining 
liver can regenerate to the original size within one to two weeks. A cirrhotic liver, 
however, cannot grow back. Therefore, before resection is performed for HCC, the non-
tumor portion of the liver should be biopsied to determine whether there is an associated 
cirrhosis. The biggest concern about resection is that the patient may develop post-
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operational liver failure, which can occur if the remaining portion of the liver is inadequate 
to provide the necessary support for life. 
6. Liver transplantation 
This is the ultimate treatment for patients with end-stage (advanced) liver disease 
of various types (e.g., chronic hepatitis B and C, alcoholic cirrhosis, primary biliary 
cirrhosis, and sclerosing cholangitis). Survival rates for these patients without HCC are 
90% at one year, 80% at three years, and 75% at five years. Moreover, liver 
transplantation is the best option for patients with HCC in which a single lesion is less 
than 5 cm in diameter. If more than one lesion is present, all lesions should also be less 
than 3 cm in diameter (26). Successful transplantation also requires patients to have no 
evidence of vascular invasion or metastatic disease (27). 
The most frequently encountered problem to liver transplantation is the availability 
of the donor. Although the absolute number of donors has increased over the past decade, 
it has been overwhelmed by the number of potential recipients listed for transplantation. 
Due to this rapidly escalating discrepancy between demand and supply for donor organs, 
most patients with end-stage HCC cannot be offered the opportunity for liver 
transplantation. Therefore, patients to be considered for transplantation must be very 
carefully selected. 
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Introduction II -- Molecular mechanisms: oncogenes and tumor-
suppressor genes 
Multiple genetic alterations including the activation of oncogenes and inactivation 
of tumor suppressor genes are required for malignancy in human cancers and are 
correlated with increased stages of carcinogenesis and further tumor progression. An 
oncogene is a gene that when mutated or expressed at abnormally-high levels contributes 
to converting a normal cell into a tumor cell, possibly resulting in cancer. A proto-
oncogene or oncogene precursor is a normal gene that can become an oncogene, either 
after mutation or increased expression. The proto-oncogenes that have been identified so 
far have many different functions in the cell. Many of them code for proteins that help to 
regulate cell growth and differentiation, and they are often involved in signal transduction 
and execution of mitogenie signals. Mutations in these genes distort the function of the 
associated proteins, resulting in abnormal growth and differentiation. Oncogenic versions 
of the ras genes were first identified in human tumors in 1982. It was an important 
oncogene because the three human ras genes represent the most frequently mutated 
oncogenes in human cancers. Since then, much research effort has been made to identify 
the function of ras both in normal and neoplastic cells (28). Another most commonly 
overexpressed oncogene in human cancers is the myc gene. Mutations in the myc gene 
have been found in many different cancers, including Burkitt's lymphoma, B-cell leukemia, 
and lung cancer (29). 
Tumor suppressor genes are genes that reduce the probability of a cell in a 
multicellular organism to turn into a tumor cell. A mutation or deletion of such a gene 
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will therefore increase the probability of the formation of a tumor. Unlike oncogenes, 
tumor suppressor genes usually require that both alleles that code for a particular gene 
must be affected before the effect is manifested. However, there are also cases where 
mutations in only one allele will cause an effect, such as p53. If a person inherits only 
one functional copy of the p53 gene from their parents, they are predisposed to cancer and 
usually develop several independent tumors in a variety of tissues in early adulthood (30). 
This condition is rare, and is known as Li-Fraumeni syndrome. However, mutations in p53 
are found in most tumor types, and so contribute to the complex network of molecular 
events leading to tumor formation (30). 
Cell cycle control 
Tumor-suppressor genes act primarily through their influence on the cell cycle. 
The life cycle of a dividing cell can be described by a four-phase cell cycle composed of 
M phase, Gi phase, S phase, and G2 phase. M phase is the phase of mitosis, when the cell 
physically divides. Gi phase is the first gap phase or growth phase, which occurs 
immediately after mitosis. During G\ the cell is synthesizing proteins and growing to 
achieve the size that a normal cell has before splitting in two during mitosis. S phase is a 
phase of DNA synthesis or replication in preparation for cell division. The G2 phase is 
characterized by DNA repair of errors that have been introduced during DNA replication, 
and by preparation for the coming mitosis. Cells that rest for extended periods between 
divisions (such as liver cells) have temporarily or permanently exited the cell cycle by 
going into the Go phase at the end of the Gi phase. 
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p53 mutation in HCC 
Thep53 gene has been mapped to chromosome 17. Mutation inp53 gene has been 
shown to be clinically significant in causing liver cirrhosis and hepatocellular carcinoma 
(31). A specific missense mutation (AGG to AGT transversion; Arg to Ser) in the p53 
gene at codon 249 has been reported in over 50% of HCC tumors and in paired blood 
samples from hepatitis B virus-endemic areas with high dietary aflatoxin intake (32). This 
exon 7 mutation is detected in individuals that come from different places including China 
(33), Nigeria (34), Guinea in West Africa (35), Egypt (36) and Thailand (37). 
Normal functions of p53 and its target genes 
This prominent tumor suppressor gene encodes a protein called p53. This protein 
is the central part of a major defensive pathway against neoplastic transformation. Loss of 
p53 function leads to tumorigenesis, and at least half of all human tumors examined 
displayp53 gene mutations (38). The p53 tumor suppressor protein plays multiple roles in 
cells. It is a nuclear transcription factor that is responsible for cell cycle regulation, 
preventing inappropriate movement of G1 cells into S phase. Expression of high levels of 
wild-type (but not mutant) p53 in response to DNA damage and other forms of cellular 
stress leads to cell cycle arrest or apoptosis. Cells lacking p53 are shown to be genetically 
unstable and thus more prone to tumors (39). 
1. p21(Wafl/Cipl/Sdil) 
Unlike other cell-cycle proteins, p53 is expressed at low levels in normal cells 
because it is extremely unstable and rapidly degraded (40). Under stressful situations, 
such as ultraviolet, p53 binds to specific DNA sequences and activate expression of 
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certain genes. The most important protein relative to cell-cycle control whose 
transcription is activated by p53 is the cyclin-kinase inhibitor (CKI) p21 (Wafl/Cipl/Sdil). 
This protein contains conserved cyclin and cdk-binding domains near the amino terminus 
of the molecule (41). These sequences allow p21 to bind almost all of cyclin-dependent 
kinase (CDK) complexes such as Cdkl-, Cdk2-, Cdk4-, and Cdk6-cyclin complexes that 
function at major transition points in the cell cycle. Binding of these cyclin complexes is 
essential for cell cycle progression in mediating both G1 and G2/M arrests (42). While 
this binding leads to an inhibition of the activity of the cyclin/cdk complex, the C-terminal 
region of p21 is also able to directly inhibit DNA replication. It binds tightly to and 
blocking the action of the DNA polymerase processivity factor PCNA (proliferating cell 
nuclear antigen), which is a DNA-tracking protein required for rapid and processive 
replication of DNA by the polymerase S and £ (43). 
2. PCNA 
The proliferating cell nuclear antigen (PCNA) is a 36 kD protein which is highly 
conserved between species. It functions as a co-factor for DNA polymerase 5 and £ in S 
phase of the cell cycle and also during DNA synthesis associated with DNA damage repair 
mechanisms. It has been suggested that expression of high levels of PCNA protein 
correlates with organ metastasis and vascular invasion. Therefore, detection of high levels 
of PCNA is suggested to be a significant marker of clinical malignancy and a factor for 
prognostic implication in various cancers such as lymphomas (44), skin cancer (45), 
laryngeal cancer (46) and breast cancers (47). 
3. Bcl-2 and Bax: the Bcl-2 family 
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When signals of survival factors such as cell stress and injury are received, p53 
activates the expression of genes that lead to apoptosis (48). The known transcriptional 
targets for p53 in promoting this programmed cell death include various pro-apoptotic and 
anti-apoptotic Bcl-2 members (49). Bcl-2 is the prototype for a family of mammalian 
genes and their proteins. They govern mitochondrial membrane permeabilisation (MMP) 
and can be either pro-apoptotic such as Puma, Noxa, Bak and Bax or anti-apoptotic such 
as Bcl-2, Bcl-xL and Bcl-w (50). Mitochondrial permeability is, therefore, determined by 
the balance between the pro-apoptotic proteins like Bax and their anti-apoptotic cousins 
like Bcl-2. The activity of these proteins is positively or negatively regulated by BH3-only 
members，the Bcl-2 family members that contain a single Bcl-2 homology-3 domain. 
These BH3-only members act as the terminal effectors of distinct signaling pathways. 
When the net dominance of the pro-apoptotic proteins is produced, the mitochondria will 
be permeabilized and will release pro-apoptotic factors. One such factor, cytochrome c, 
acts together with the cell-death adaptor Apaf-1 to trigger the activation of caspase-9, a 
cysteine protease that initiates a downstream proteolytic cascade that also involves 
caspase-3 and caspase-7. Once activated, caspases cleave proteins that are important for 
cell and genome integrity. 
Bcl-2 is a proto-oncogene located on chromosome 18 (51). This gene was 
discovered as the translocated locus in B-cell leukemia. In the majority of follicular 
lymphomas, a translocation involving chromosomes 14 and 18 is observed (52). This 
t(14;18) translocation places the bcl-2 gene close to the immunoglobulin heavy chain 
gene located on chromosome 14 (53). The heavy chain gene enhancer is very active in B 
cells and it increases the rate of transcription of the bcl-2 gene. Its product is a 26-kD 
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integral membrane protein called Bcl-2. This protein is normally located in the membranes 
of the endoplasmic reticulum (ER), nuclear envelope, and in the other membranes of the 
mitochondria. 
After receiving certain apoptotic stimuli, Bcl-2 directly or indirectly prevents the 
release of cytochrome c from mitochondria by inhibiting the actions of caspases (54). 
Evidence showed that an increased level of the Bcl-2 protects cells from apoptosis 
triggered by different stimuli (55) and enhances resistance to chemotherapeutic agents (56). 
The Bax gene encodes a 21 kD protein which belongs to one of the pro-apoptotic 
members of the Bcl-2 family. It is assumed to exert at least part of its apoptosis-inducing 
function by facilitating mitochondrial permeability transition pore opening, a process that 
is supposedly antagonized by the anti-apoptotic members Bcl-2 and Bcl-xL by the ability 
to form heterodimers (57). Its gene expression is regulated by p53 through a DNA-
binding response element located within the Bax promoter (58). However, this regulation 
of Bax expression by wild-type p53 was demonstrated to be cell type specific. In the 
mouse, Bax expression following ionizing radiation was seen in the prostate, thymus, 
spleen, small intestine, and lung, as well as sympathetic, Purkinje, and olfactory cortical 
neurons. In the kidney, heart, liver, and brain, however, no p53-dependent regulation of 
Bax could be observed (59). In addition, several tumor-derived p53 mutants have been 
identified that are capable of activating transcription through the promoter of thep21 gene 
but not through the Bax promoter (60). It suggests that a failure in the ability of p53 to 
transactivate the Bax gene may play an important role in tumor formation. 
Bax has been reported to be an integral membrane protein associated with 
organelles or bound to organelles by a soluble protein found in the cytosol. Confocal 
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microscopy revealed that GFP-Bax was distributed diffusely throughout the cytosol. 
Upon induction of apoptosis, however, Bax moved intracellularly and redistributed itself 
to organelles to promote cell death (61). 
4. Mdm2 
Wild-type p53 is a key regulator that controls cell growth by functioning as a 
transactivator of gene expression. The control of the expression of this protein is, 
therefore, essential for normal growth and development. It has been reported that p53 is 
regulated at the level of transcription, translation, change in conformation and covalent 
and non-covalent modifications (62). 
p53 has been reported to undergo degradation directed by Mdm2 through an 
ubiquitin-dependent pathway (63). Mdm2 is a 90-kD oncoprotein that negatively 
regulates the activity of p53. It functions as a p53-specific E3 ubiquitin ligase in vitro, and 
the ubiquitinated p53 is degraded on 26S proteasomes (64). Furthermore, it recognizes the 
N-terminal activation domain of the p53 transcription factor and blocks the ability of p53 
to associate with factors involved in gene transcription. The mdm2 shuttling between 
the nucleus and the cytoplasm is essential for mdm2 activity to target p53 for degradation 
(65). The negative regulation of p53 functions by mdm2 is important as shown in a study 
that inactivation of mdm2 by gene disruption was lethal for early mice embryos. However, 
lethality of the mice was rescued by the simultaneous disruption of the p53 gene (66). 
Importantly, mdm2 itself is the product of a p53-inducible gene. p53 binds the 
mdm2 P2 promoter and transcriptionally up-regulates mdm2 expression. An increase in 
Mdm2 causes a decrease in p53 activity, which subsequently results in a decreased Mdm2 
to constitutive levels. Mdm2 can also ubiquitinate itself and induce its own degradation. 
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Thus, an autoregulatory feedback loop has been established between p53 and Mdm2, in 
which p53 induces expression of its own antagonist (67). 
The mdm2 protein also has p53-independent functions. Evidence has shown that 
mdm2 interacted directly with p21 both in vitro and in vivo with the binding region in 
amino acids 180-298 of the mdm2 protein (68). It was suggested that mdm2 was also a 
negative regulator of p21. 
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Introduction III — Evaluation of the effects of hepatocarcinogenesis 
GST-P 
Glutathione S-transferases (GSTs) are dimeric multifunctional and multigene 
family proteins. They are versatile enzymes and participate in nucleophilic attact of the 
sulfur atom of glutathione on electrophilic centers of xenobiotic compounds. Of all 
classes of GST (a, 兀，a, 9), GST-pi, a 24-KDa GST isoform, has significance in 
diagnosis of cancers. Placental GST-P, the only GST of the pi class in rats, is normally 
absent in rat hepatocytes. It becomes specifically induced at an early stage of chemical 
hepatocarcinogenesis (69). It is then expressed constitutively and is present at high levels 
in preneoplastic hepatocytes and HCCs. Therefore, it appears to be a valuable marker for 
HCC in rat. 
In addition, GST-pi was also shown to be higher in other tumors. In an 
immunohistochemistry retrospective study, it was demonstrated that GST-pi expression 
could be a marker for astrocytomas tumoral progression (70). In another study it was 
suggested that neoplastic processes increase the expression of placental isozyme of GST-
pi and also affect metabolic pathway involved in bile acid synthesis. Thus placental form 
of GST-P as new marker enzyme for preneoplastic hepatocytes, but it is not found that 
human placental form, GST-pi to be possible tumor marker for various human tissues 
except liver (71). 
ALT& AST 
The enzyme alanine aminotransferase is widely reported in a variety of tissue 
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sources. The major source of ALT is of hepatic origin and has led to the application of 
ALT determination to the study of hepatic diseases. Elevated serum levels are found in 
hepatitis, cirrhosis, and obstructive jaundice. ALT determinations via ultraviolet methods 
were first developed in 1956 by Wroblewski and LaDue (72). The method was based on 
the oxidation of NADH by lactate dehydrogenase (LDH) in the reactions below: 
L-Alanine + a-ketoglutarate ALT 一 Pyruvate + L-Glutamate 
Pyruvate + NADH + H" LDH 一 L-Lactate + NAD" + H2O 
Aspartate Transminase (AST) is one of several enzymes that catalyze the exchange 
of amino and 0x0 groups between a-amino acids and a-oxo acids. It is widely distributed 
throughout body tissues with significant amounts in heart and liver. Lesser amounts are 
found in skeletal muscles, kidneys, pancreas, spleen, lungs and brain. Injury to these 
tissues results in release of AST enzyme to the general circulation. An increase in serum 
AST is also found with hepatitis, liver necrosis, cirrhosis and liver metastasis. The 
enzyme reaction is as follows: 
L-Aspartate + 2-Oxoglutarate AST 一 Oxalacetate + L-Glutamate 
Oxalacetate + NADH + H" MDH 一 L-Maltate + NAD" + H2O 
20 
Introduction IV — Traditional Chinese Medicine (TCM) 
Traditional Chinese Medicine (TCM) is an integral part of Chinese culture. It has 
made many contributions to the aspect of herbal medicine and has become widely 
accepted as an alternative therapy to treat different diseases. Today, both of TCM and 
western medicine are being used in providing medical and health services worldwide. 
TCM is recognized for its effectiveness in enhancing energy, lowering recurrence in some 
cancers and offsetting side effects that caused by chemical treatment of cancer in 
conventional treatment. 
Andrographis Paniculata 
Andrographis Paniculata (AP) is a traditional Chinese herbal drug for the treatment 
of various diseases. It belongs to a plant family called Acanthaceae and is commonly 
called "the King of bitters" or Chuan Xin Lian in Chinese. Andrographis Paniculata 
grows abundantly in southeastern Asia like India, Pakistan and Indonesia. It, however, is 
mostly cultivated in China, Thailand, the East and West Indies. The aerial parts of the 
plant (leaves and stems) are used in combination with other herbs to treat diseases such as 
GI tract and upper respiratory infections, fever, herpes, sore throat, and a variety of other 
chronic and infectious diseases. However, there is not much research on the TCM until 
recent years. Since then, this plant has been extensively studied and early study has 
confirmed that Andrographis Paniculata possesses a broad range of pharmacological 
properties (73-75). 
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The extraction of the active phytochemicals from the leaves of this plant reveals 
that one of the major components, andrographolide, is medicinally active. This primary 
medicinal component of Andrographis is a diterpene lactone, which has the structure of 20 
carbon atoms arranged as four isoprene units (Fig. 1). The cyclic ester lactone in the 
compound is believed to be the major active part that possesses the medicinal effects. 
Other medicinal components like deoxyandrographolide, -19p-D-glucoside, neo-
andrographolide, 14-deoxy-l l，12-didehydroandrographolide (andrographolide D), 
homoandrographolide, andrographan, andrographon, andrographosterin, and stigmasterol 
have also been isolated from this plant. 
In recent years, the pharmacological effects, safety, efficacy and mechanisms of 
action of andrographolide have been described. Previous study indicated that 
andrographolide was widely distributed throughout the body when orally administered to 
rats. Its half life is short, of approximately 6 hrs, and the compound is metabolized and 
excreted in urine and bile (76). Other studies suggested that andrographolide possesses 
the medicinal properties such as anti-inflammatory, antibacterial, antipyretic, immune 
enhancer, anticancer, and in particularly hepatoproteclive (77-79). 
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Fig 1. Andrographis Paniculata (on the left), and its active component, andrographolide 
(on the right). 
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Pharmacological properties of andrographolide 
In a recent study by Iruretagoyena et al. (2006), andrographolide was shown to be 
able to interfere with NF-k;B activation in mouse M L E - 1 2 cells. N F - k B is a transcription 
factor that is known to play a central role in immune and inflammatory responses. By 
interfering with this activation, dendritic cells (DCs) that were treated with 
andrographolide failed to mature in response to LPS and to activate antigen-specific T 
cells in vitro (80). 
Its anti-inflammatory mechanism was evaluated in another study. 
Andrographolide was able to inhibit Complement 5a (C5a) -induced chemotatic migration 
of macrophages. It significantly attenuated C5a-stimulated phosphorylation of ERK 1/2, 
and of its upstream activator, MAP kinase-ERK kinase (MEK V2). Inhibition of cell 
migration was also observed in response to macrophage inflammatory protein-1 a (MlP-la) 
(81). Qin LH et al. (2006) investigated the effect of andrographolide on the production of 
TNF- a and IL-12 (Interleukin-12), the two major inflammatory mediators secreted by 
macrophages, in murine peritoneal macrophages. The results revealed that 
andrographolide significantly reduced TNF- a and IL-12a and IL-12b at mRNA level, and 
decreased the production of TNF- a and IL-12p70 proteins in a concentration-dependent 
manner. The mechanism of the inhibition of LPS-induced production of TNF- a was 
found to be due to the suppression of the ERK 1/2 signaling pathway (82). 
Andrographolide has also been shown to be a remedy for fever, pain reduction 
and disorders of the intestinal tract (83). There was a reduction in rectal body temperature 
of rats for 30, 100, and 300 mg of andrographolide/kg of body weight. While the analgesic 
activity of andrographolide was weak compared to aspirin, the anti-pyretic activity was 
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comparable to that of aspirin. It was found that 300 mg/kg body weight of andrographolide 
was as effective as the same amount of aspirin, in fact, the AP extract was found to 
possess antiulcerogenie activity. It reduced the development of ulcers by 31%, while the 
standard ulcer drug, cimetidine had an 85.43% reduction rate. Thus, andrographolide 
caused a significant decrease in total stomach acidity and acid stomach juice secretion, 
without the cost and side effects associated with ulcer therapy (83). 
Furthermore, the crude extract and isolates of Andrographis Paniculata, 
andrographolide, showed viricidal activity against herpes simplex vims 1 (HSV-1) (73). 
The anti-cancer property of the compound was suggested and confirmed by a most 
recent study on breast cancer cells. In cell cycle studies, andrographolide effectively 
inhibited the growth of breast cancer cells by blocking the cell cycle at GO/Gl phase. The 
effect was similar to Lovastatin, which was the positive control in this study. This 
inhibition was due to its interaction with some cell cycle proteins, like p27 & CDK4. In 
vivo studies showed that cell cycle inhibitor p27 was increased upon treatment of 
andrographolide, which subsequently led to a decrease in CDK4. An early study 
demonstrated that andrographolide had potent cell differentiation inducing activity on 
mouse leukemia cells and thus causing maturation of cancer cells (84). 
Andrographolide was also shown to be hepatoprotective (85). Pretreatment of 
mice with andrographolide for three consecutive days produced significant decrease in 
malondialdehyde formation, reduced glutathione (GSH) depletion and enzymatic leakage 
of glutamic-pyruvate transaminase (GPT). Other diterpenes extracted from AP also 
showed a comparable hepatoprotective effect with silymarin in terms of the formation of 
the degradation products of lipid peroxidation and release of GPT in the serum. 
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Andrographolide also showed a significant increase in the percent viability on the ex vivo 
preparation of isolated rat hepatocytes against paracetamol-induced toxicity. It was found 
to be more potent than the standard hepatoprotective agent, silymarin (79). 
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Introduction V ~ Aim of the project 
Although the beneficial effects of andrographolide have been reported in the 
previous studies, its biological in the liver has yet to be elucidated. Therefore, the purpose 
of my present study is to investigate the effects of andrographolide on liver through in 
vitro and in vivo studies. 
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Materials & Methods — In vitro 
In this part of the experiment, the biological activity of andrographolide in liver 
cancer cell line was investigated. Neutral red assay, cell cycle analysis, DNA 
fragmentation, and cDNA microarray were employed to study the effects of the active 
component on HepG2 cells. 
Chapter 1: Effects of andrographolide on cell viability and cell cycle 
Neutral red assay, flow cytometry & DNA fragmentation 
1.1 Materials & Solutions 
Trypsin-EDTA (IX), Dulbecco's Modified Eagle Medium Invitrogen (Ca., USA) 
(DMEM), RPMI Medium 1640, PSN Antibiotic mixture 
Fetal Bovine Serum (FBS) Biosera (UK) 
Sodium chloride (NaCl), potassium chloride (KCl), sodium USB (Cleveland, USA) 
dodecyl sulfate (SDS), agarose, proteinase K, bromophenol 
blue 
Sodium phosphate (NaHiPCU), potassium (KH2PO4), Sigma Chemicals (St. 
neutral red (NR), sodium bicarbonate (NaHCO�)，propidium Louis, USA) 
iodide (PI), ethylenediaminetetraacetic acid (EDTA), xylene — 
cyanole, ethidium bromide (EB) 
Andrographolide (AND) 98% Sigma-Aldrich (USA) 
Dimethylsulfoxide (DMSO ) Fisher Scientific (USA) 
DNA ladder (GeneRuler) Fermentas (Ont. Canada) 
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RNase A Amersham (USA) 
Steritop-GP 500 ml (0.22 |im), millex-GP (0.22 ^m) Millpore (Ma., USA) 
75 cm culture flask, 96-well microplate Iwaki (Tokyo, Japan) 
60 mm culture dish Coming (USA) 
Flow cytometer Beckman Coulter (USA) 
1.2 Preparation of solutions 
RPMI: The medium was prepared by dissolving one pack of RPMI medium and 2.0 g of 
NaHCOs in 895 ml of dHsO. After the powder was completely dissolved, the solution was 
adjusted to pH 7.2. The solution was sterilized in the culture hood by filtering through a 
Steritop membrane with pore sizes of 0.22 [im. Fetal bovine serum (100 ml) and PSN 
antibiotic mixture (2 ml) were added to the filtered solution and the completed medium 
was stored at 4°C. All containers for cell culture use were sterilized. 
DMEM: The medium was prepared by dissolving one pack of DMEM medium and 3.7 g 
of NaHCOs in 895 ml of dHiO. After pH was adjusted to 7.2, membrane filtration was 
performed in the culture hood. Before use, 100 ml of FBS and 2 ml of PSN antibiotic 
mixture were added to the filtered solution and the completed medium was stored at 4°C. 
The containers for cell culture use were sterilized. 
10 X Phosphate-buffered saline (PBS): The solution contained 80 g ofNaCl, 2 g of KCl, 
14.4 g of NaH2P04, and 2.4 g of KH2PO4 in 900 ml of 恥 0 . The pH of the solution was 
adjusted to 7.4, and the volume was made up to 1000 ml with dHzO. 
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1 X PBS: It was made by diluting 100 ml of 10 X PBS with 900 ml of dEbO. This 
solution was autoclaved for cell culture use. 
Andrographolide (AND) stock solution (2QmM): It was made by dissolving 7.6 mg of 
AND in 1.08 ml of DMSO. Different concentrations of AND were prepared by diluting 
the stock solution with culture medium. 
NR solution: The solution was made by dissolving 1 g of NR in 200 ml of 1 X PBS, 
followed by membrane filtration using Millex GP with pore size of 0.22 \im. 
Lysis buffer: It contained 200 mM Tris-HCl, pH 8.3, 100 mM EDTA and 1% SDS 
Proteinase K solution (10 mg/ml): The solution was made by dissolving 5 mg of 
proteinase K in 0.5 ml of dHzO. 
6 X DNA loading dye: It was made up of 93.6 |il of glycerol, 3 jil of 0.5 M EDTA (pH 
8.0), 0.3 mg of bromophenol blue, 0.3 mg of xylene cyanole and dHzO to a final volume 
of 250 
10 X Tris-Borate-EDTA (TBE) buffer: The buffer was prepared by dissolving 108 g of 
Tris base, 55 g of Boric acid and 9.3 g of Na4EDTA in 1000 ml of distilled water. 
Ethidium bromide (EB): It was prepared by dissolving 50 mg of EB in 100 ml of dHsO. 
1.3 Procedures 
1.3.1 Seeding cells into culture flask (performed inside culture hood) 
Cells stored in liquid nitrogen were thawed in a 37°C water bath, along with 1 X 
PBS and completed medium. Cells were transferred to a new tube and were centrifliged at 
1,000 rpm for 3 min. The supernatant was discarded and the cell pellet was washed twice 
with PBS by centrifugation at 1,000 rpm for 3 min. The supernatant was discarded and 1 
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ml of the completed medium was added to resuspend cells. After that, cells were 
transferred to a new 75 cm culture flask with 12 to 15 ml of warm medium. The flask 
was stored in a 37°C incubator supplied with 5% CO2. 
1.3.2 Subculturing technique (performed inside culture hood) 
The medium was discarded from the 75 cm culture flask and cells were rinsed 
with warm PBS twice to remove any trace of serum. Trypsin-EDTA (1 ml) was added to 
the flask and incubated at 37°C. After a few minutes, four milliliters of completed 
medium were added to stop the activity of trypsin. The cells were transferred to a new 
tube and spinned at 1,000 rpm for 3 min. The supernatant was discarded and the cell 
pellet was resuspended in warm medium. Cells were washed again by centrifugation at 
1000 rpm for 3 min, and were resusp ended in 1 ml medium. Subsequently, 2 of cells 
was added to 18 |LI1 of dye and the mixture was placed onto a hematometer for cell 
counting. Approximately 0.5 ml of 1 x 10^ cells was seeded in a new 75 cm� culture flask 
with 12 ml of fresh medium. The culture flask was put inside a 37°C incubator with 5% 
CO2. 
1.3.3 Neutral red assay (cell viability test for HepG2, WRL 68 & Clone 9 cells) 
The inhibitory effect of AND on cell viability was measured by neutral red assay. 
HepG2, the human liver cancer cells, were thawed from stock using RPMI medium. After 
several subcultures, 100 )il of 1 x lO. cells was seeded onto 96-well plates and allowed to 
be pre-treated for 24 hrs. After that, attached cells were incubated with 100 |il of 1% 
DMSO as the control or different concentrations of AND. The plates were incubated at 
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various time periods: 24, 48 and 72 hrs. After treatment, the culture medium was removed 
and cells were washed with 200 fil of non-sterilized PBS twice. Then, neutral red solution 
(50 |il) was added to all the wells except the blank. The plates were wrapped in aluminum 
foil and incubated for 1 hr at 37°C. After that, wells were washed with 200 |il of PBS 
twice and the plates were inverted and allowed to dry in a 65°C oven. To each well of the 
plates, 100 |il of 1% SDS was added. The plates were shaken for 2 min and placed in a 
microplate reader to measure the absorbance at 540 nm. The cell viability (%) was plotted 
against the concentration of AND and the IC50, the concentration of the agent that reduced 
the cell viability by 50%, was recorded. 
The same procedure was applied to human normal liver embryo cells, WRL 68, 
and rat normal liver cells, Clone 9, except that the culture medium was DMEM for these 
two cell lines. 
1.3.4 DNA purification of HepG2 cells 
Apoptotic cells were detected by DNA fragmentation. Approximately 1 x 10^  
HepG2 cells were seeded onto a 60 mm culture dish and incubated with 1% DMSO or 
different concentrations of AND (12.5, 20, 25 and 50 fiM). After 72 hrs, cells were 
harvested and washed with PBS by centrifugation at 1,000 for 3 min. The cell pellet was 
resuspended in 400 pi of lysis buffer in a 1.5 ml microtube with gentle vortexing. When 
no cell debris was left, 20 |j.l of 10 mg/ml of proteinase K was added to each tube and the 
lysed cells were incubated at 37°C for 3 hrs. After samples were cooled to room 
temperature, 150 |il of saturated NaCl solution was added and the contents were mixed by 
vigorous shaking. The tubes were then centrifuged at 7,000 rpm for 15 min at room 
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temperature. The supernatant containing DNA was poured to a new tube, and 1 ml of cold 
ethanol was added. After the tube was inverted several times, it was centrifuged at 14,000 
rpm at 4°C for 20 min. Samples were washed once with 70% EtOH and the DNA pellet 
was allowed to air dry for 15 to 20 min. TE buffer (20 to 50 jul) containing 0.2 mg/ml of 
RNase A was added to each DNA pellet. The samples were incubated at 37°C for 90 min. 
About 2 }il of the DNA solution was added to 998 |il of TE buffer and concentration was 
measured using UV spectrophotometry (Beckman, DU 650) with OD260. 
1.3.5 DNA gel electrophoresis 
DNA gel electrophoresis was performed to detect DNA fragmentation. DNA gel 
containing 1.5% (w/v) agarose and 0.5 X TBE was boiled to completely dissolve the 
agarose. The gel solution was mixed thoroughly and 5 |Lig/mL of EB was added when the 
solution had cooled down to room temperature. Then the solution was poured into a gel 
casting mould for solidification. After the concentration of each sample was adjusted to 
625 |ig/ml, 10 |Lil of DNA samples were mixed with 2 |il of 6 X DNA loading dye and the 
mixture was loaded into the wells. The gel was run at 60 V for 45 min in 0.5 X TBE 
buffer. Electrophoresis was completed when the bromophenol blue had migrated down 
2/3 of the length of the gel. The DNA bands were visualized under UV illuminator (UVP) 
and photographed for record. 
1.3.6 Flow cytometry (cell cycle analysis) 
The nuclear DNA content was measured by using propidium iodide (PI) staining 
and fluorescence-activated cell sorting (FACS) analysis. HepG2 cells were counted and 
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approximately 1 x 10^ cells were seeded onto a 60 mm culture dish and cells were pre-
incubated for 24 hrs. After incubation with 1% DMSO or 12.5, 20 and 25 uM of AND for 
24 and 48 hrs, floating cells in the spent medium and adherent cells were collected by 
combining the spent medium and trypsin-treated samples. Cells were harvested by 
centrifligation at 1,000 rpm for 3 min. The medium was discarded and the cell pellet was 
washed once with 1 ml PBS by centrifligation. The cell pellet was resuspended with 0.1 
ml PBS and fixed in 1 ml of ice-cold 70% ethanol. The cell suspension was allowed to 
store overnight at 4°C. After fixing, cells were washed once with 1 ml PBS by 
centrifligation at 1,000 for 3 min at room temperature and resusp ended in 1 ml PBS 
containing 8 fig/ml of RNase A and 40 昭/ml of PI. Samples were then incubated at 37°C 
for 15 to 30 min and DNA content was analyzed using a FACScan flow cytometer. 
The total number of cells counted was set to 10,000. The DNA profile was 
represented in ID plot (histogram), where the x-axis is the channel number and y-axis the 
number of events. After the profiles were obtained, the data was analyzed using FCS 
Express (Version 2) software by De Novo Company. The histograms showing the DNA 
profiles of the control and AND-treated groups were compared and the number of cells 
suspending in Sub Gi, G q / G i , S and G2/M phases were counted. 
Chapter 2: Effects of andrographolide on gene expressions 
mRNA extraction from cells and cDNA micro array 
2.1 Materials & Solutions 
Agarose, diethyl pyrocarbonate (DEPC), MOPS, USB 
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Chloroform, EDTA, isopropanol, formaldehyde, tris, Sigma 
deionized formamide, ethidium bromide (EB) 
Trizol reagent Gibco BRL 
Ethanol (EtOH) B m 
Oligo GEArray Human Toxicology & Drug Super Array, Bio-Gene Tech. 
metabolism microarray membrane (OHS-401), 
ArrayGrade cRNA cleanup kit, 
TrueLabelling-AMP 2.0, 
Oligo GEArray Reagent Kit 
Biotin-16-UTP Roche Applied Science 
2.2 Preparation of solutions 
Diethyl pvrocarbonate (DEPQ-treated water: DEPC was added to autoclaved nano-pure 
water to make a final concentration of 0.1% by volume. It was stirred overnight and 
autoclaved before use. 
1 X TE buffer: It contained 10 mM Tris-HCl and 1 mM EDTA. The pH was adjusted to 
8.0 with HCl. 
10 X MOPS: It was prepared by dissolving 83.72 g of MOPS in 450 ml of DEPC-treated 
dHiO, and pH was adjusted to 7.0. Then 8.203 g ofNaOAc and 3.722 g of EDTA were 
added to the solution. A final volume of 500 ml was made up with DEPC-dHiO. 
34 
RNA sample buffer: It contained 10 ml of deionized formamide, 3.5 ml of 12.3 
formaldehyde, 1 ml of 10 X MOPS buffer and 1 ml of DEPC-treated water and stored at -
20°C. 
6 X RNA loading dye: It was made up of 10 mM of EDTA (pH 8.0), 50% (v/v) glycerol, 
0.25% bromophenol blue (w/v) filter-sterilized and stored at -20°C. 
2.3 Procedures: 
2.3.1 Cell treatments 
HepG2 cells (5 x 10^) were seeded in a culture flask for 24 hrs in a 37°C incubator. 
After incubation, cells were treated with 1% DMSO or 16 uM of AND for 48 hrs. The 
medium was discarded and cells were trypsinized and washed with PBS twice by 
centrifugation at 1,000 rpm for 3 min. 
2.3.2 mRNA extraction from cell 
a) Cell lysis: 0.5 ml of Trizol reagent was added to the cell pellet, vortexed and stored at 
room temperature for 10 to 15 min. It was then centrifuged at 12,000 g for 10 min at 
4°C. The supernatant was transferred to a new tube. 
b) RNA Extraction: 0.1 ml of chloroform was added to the supernatant, and mixed 
vigorously. The sample was stored at room temperature for 10 to 15 min. It was then 
centrifuged at 12,000 g for 15 min at 4�C. 
c) RNA Precipitation: the aqueous layer, which contained RNA, was transferred into a 
new tube. Isopropanol (0.25 ml) was added and stored at room temperature for 10 min. 
The sample was centrifuged at 12,000 g for 15 min at 4°C. 
35 
d) RNA Wash: the RNA pellet was mixed with 0.5 ml of 75% ethanoL It was then 
centrifuged at 7,500 g for 5 min at 4°C. 
e) Solubilization: ethanol was discarded and the RNA pellet was allowed to air dry for 15 
to 30 min. It was dissolved in 50 [d of DEPC-treated dH^O and incubated at 55 to 
6 0 � C f o r 10 min. 
f) Storage: It was kept at -20°C for temporary storage or at -70°C for a long term storage. 
2.3.3 Determination of total RNA yield and quality yield 
The RNA sample was diluted in 1:500 with 1 X TE buffer. The yield of total RNA 
was obtained by UV spectrophotometry (Beckman, DU 650) at wavelength 260 nm, using 
1 X TE buffer as blank. The amount of total RNA was calculated by the formula that 1 
A260 unit has 40 [ig/m\ of single stranded RNA. The result was divided by 2 as the 
dilution factor. The quality of RNA was assessed by the ratio of A260/A280. The integrity 
of the RNA was determined by formaldehyde agarose gel electrophoresis. The ratio of 
28S and 18S ribosomal RNAs was close to 2:1 after EB staining. 
2.3.4 RNA formaldehyde agarose gel eletrophoresis 
The agarose gel was prepared by dissolving 0.3 g of agarose in 14.4 ml of DEPC-
treated water. The solution was heated in a microwave to completely dissolve the agarose. 
When the mixture was cooled down for a few minutes, formaldehyde and 1 X MOPS were 
added to the gel solution. It was mixed thoroughly, and was poured into the gel casting 
mould for solidification. 
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Table 2.3.4 Protocol for formaldehyde agarose gel 
Agarose 0.3 g or 1.5% (w/v) 
DEPC-treated water 14.4 ml 
1 X MOPS ^ 
Formaldehyde 3.6 ml 
The RNA sample for gel electrophoresis was prepared by mixing 2 to 3 fig of RNA 
with 10 |Lil of RNA sample buffer, 1 |LI1 of RNA loading dye and DEPC-treated water to 
make a final volume of 20 pi. The mixture was heated to 65°C for 10 min, and allowed to 
cool to room temperature before loaded into the gel. 
After samples had been loaded into the wells, the gel was run in 1 X MOPS buffer 
at 120 V for 20 min or until the bromophenol blue dye had migrated down 2/3 of the 
length of the gel. The gel was stained with 5 ug/ml of EB for 30 min and then destained 
with three rinses of DEPC-treated water. The RNA bands were examined under UV 
illuminator (UVP) and it was photographed for record. 
2.3.5 cDNA synthesis 
Table 2.3.5 cDNA Super Array kit components 
Tube Contents 
G1 TrueLab eling Primer 
Rl RNase Inhibitor 
G2 cDNA Synthesis Enzyme Mix 
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ra 5 X cDNA Synthesis Buffer 
H ^ RNase-free H2O 
^ 2.5 X RNA Polymerase Buffer -
G25 RNA Polymerase Enzyme 
Spin columns 
Elution Tubes 
GEAhyb. Hybridization solution 
Solution Q 
5X buffer F 
AP-SA 
Buffer G 
CDP-Star chemiluminescent substrate 
The components in GI, G3, H2O, and G24 were thawed, mixed and collected at the 
bottom of the tube with a brief spin in a microcentrifuge. 
a) Preparation of the annealing mixture 
In a sterile PGR tube, 3.0 fig of total RNA (extracted in section 2.3.2), 1.0 |j.l of 
GI and RNase-free H2O were added to make a final volume of 10 \i\. The contents 
were mixed well followed by a brief centrifugation to collect the mixture at the 
bottom of the tube. Samples were incubated at 70°C for 10 min, then centrifuged 
briefly and placed on ice. 
b) Preparation of the cDNA synthesis master mix 
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cDNA synthesis master mix Per reaction 
RNase-free H2O ' ^ l 
5 X cDNA Synthesis Buffer (G3) 4 0 ~ 
RNase Inhibitor (RI) f j l i 
cDNA Synthesis Enzyme Mix (G2) l ]d 
Final volume 10 |il 
The components were combined in the order listed above, and mixed well with 
pipetting up and down two to three times followed by brief centrifugation to collect 
the mixture at the bottom of the tube. The cDNA synthesis master mix was then 
placed on ice. 
c) cDNA Synthesis reaction: To each tube containing 10 |il of annealing mixture, 10 )il of 
cDNA synthesis master mix was added. The components were mixed well and then 
centrifuged briefly. Each reaction tube was incubated at 42°C for 50 min followed by 
75°C for 5 min then cooled to 37°C. 
2.3.6 cRNA synthesis, labeling and amplification 
a) Preparation of the amplification master mix 
Amplification master mix Per reaction 
2.5 X RNA Polymerase Buffer (G24) 
Biotin-UTP 
RNA Polymerase Enzyme (G25) 2 fil 
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Final volume 20 fil 
The above components were well mixed with pipetting up and down two to 
three times followed by brief centrifugation. 
b) cRNA Synthesis reaction: To each tube containing 20 |il of cDNA synthesis reaction, 
20 fil of amplification master mix was added. The components were mixed gently and 
centrifuged briefly. Then the reaction tubes were incubated overnight at 37°C. 
2.3.7 cRNA purification 
a) Binding cRNA to the Spin Column: A spin column was set up in a collection tube for 
each sample. RNase-free H2O (60 fil) was added to each cRNA synthesis reaction 
tube for a final volume of 100 jil. The entire reaction mixture was transferred to one 
1.5-ml RNase-free tube. Lysis & binding buffer (G6) (350 pi) was added to each of 
the reaction mixture. The contents were mixed well with gentle pipetting for two to 
three times. Then 350 |il of room temperature ACS-Grade 100% ethanol was added 
and contents were mixed well with gently pipetting. Each sample was loaded to the 
center of its own spin column and centrifuged for around 30 sec at 8,000 x g. The 
column was removed from the tube and the flow-through was discarded. 
b) Washing the spin column: To each spin column, 600 |xl of washing buffer (G17 with 
ethanol) was applied. The column was centrifuged for about 30 sec at 8,000 x g. The 
column was removed and the flow-through was discarded. The column was placed 
back into the collection tube. Then 200 pi of washing buffer (G17 with ethanol) was 
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applied to each spin column, and the column was centrifuged for 3 min at 11,000 x g. 
c) Eluting the cRNA from the spin column: Each spin column was transferred to a fresh 
elution tube. To the center of each spin column, 50 pi of room temperature RNase-
free 10 mM Tris buffer pH 8.0 (G26) was added. The spin column was incubated at 
room temperature for 2 min, followed by centrifugation for 1 min at 8000 x g. After 
the entire volume of buffer passed through the filter, the purified cRNA was stored on 
ice. 
d) cRNA quality assessment: The quality of cRNA was assessed by UV 
spectrophotometry as described previously. 
2.3.8 Oligo GEArray hybridization 
a) Pre-hybridization: To pre-wet the array membrane, roughly 5 ml of deionized water 
was added to the hybridization tube. The cap was screwed on hand-tight and the tube 
was allowed to sit inverted for 5 min. The GEAhyb Hybridization solution was 
warmed to 60°C and the bottle was inverted several times to allow complete 
dissolution of the buffer components. The deionized water was discarded from the 
hybridization tube and 2 ml of pre-warmed GEAhyb hybridization solution was added. 
The tube was briefly vortexed and placed in the hybridization cylinder. After checking 
that the warm hybridization tubes and cylinders were sealed hand-tight, the tubes were 
pre-hybridized in the hybridization oven at 60°C for 2 hours with continuous but slow 
agitation at 5 to 10 rpm. 
b) Hybridization: At least 2 |ig of biotin-labeled cRNA target was added to 0.75 ml of 
pre-warmed GEAhyb hybridization solution and mixed well. Then the pre-
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hybridization solution was discarded from the hybridization tube and the target 
hybridization mix containing the labeled cRNA target was added to the tube. 
Hybridization was continued overnight at 60°C with slow agitation at 5 to 10 rpm. 
c) Preparation of wash solutions: Wash solution 1 (2 X SSC, 1% SDS) was prepared by 
mixing 10 ml of 20 X SSC with 5 ml of 20% SDS and 85 ml ofdHsO. Wash solution 
2 (0.1 X SSC, 0.5% SDS) was prepared by mixing 0.5 ml of 20 X SSC with 2.5 ml of 
20% SDS and 97 ml of dHiO. Both wash solutions 1 and 2 were warmed to 60�C 
before use. The preparations of 20 X SSC and 20% SDS were as follows: 
20 X SSC (pH 7.0) 
Sodium Chloride (NaCl) 2.63 g 
Sodium citrate dihydrate 1.323 g 
Distilled water 10 ml 
20% SDS 
Sodium dodecyl sulfate (SDS) 200 g 
Distilled water 1 L 
d) Washing: The target hybridization mix was transferred to a clean microcentrifuge tube 
and 5 ml of wash solution 1 was added to the hybridization tube. The tube was placed 
back into the hybridization oven and the membrane was washed at 60°C with faster 
agitation at 20 to 30 rpm for 15 min. The wash solution was discarded and 5 ml of 
wash solution 2 was added. The membrane was washed for 15 min at 60°C with 20 to 
30 agitations. The wash solution was immediately discarded and the cap was placed 
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back on the hybridization tube to prevent membrane from drying. The tube was 
allowed to cool to room temperature. 
2.3.9 Chemiluminescent detection 
a) Blocking the Oligo GEArray: GEAblocking solution Q (2 ml) was added to the 
hybridization tube and vortexed briefly. The tube was incubated for 40 min with 
continuous agitation at 20 to 30 rpm. 
b) Preparation of solutions 
i) 1 X Buffer F: 5 X Buffer F was diluted five-fold with dEbO. 
ii) Dilute AP-SA Buffer: AP-SA was diluted in 1:8,000 with 1 X Buffer F. For 8 
Oligo GEArrays, 2 |li1 of AP-SA was added into 16 ml of 1 X Buffer F. 
c) Binding of alkaline phosphate-conjugated streptavidin (AP): After GEAblocking 
solution Q was discarded from the tube, 2 ml of diluted AP-SA buffer was added and 
incubated for exactly 10 min with continuous but gentle agitation (5-10 rpm). 
d) Washing: The membrane was washed four times with 4 ml 1 X Buffer F for 5 min 
with gentle agitation. The tube was well vortexed after each addition of fresh IX 
Buffer F. 
e) Rinsing: After the last wash was discarded, 3 ml of Buffer G was added and the tube 
was inverted three times. The buffer was discarded and the procedure was repeated 
twice. 
f) Detection: After rinsing, 1.0 ml CDP-Star chemiluminescent substrate was applied to 
the hybridization tube. The tubes were rotated in room temperature hybridization oven 
for 3 to 5 min. 
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g) Image acquisition: After the CDP-Star incubation, the GEArray was ready for image 
acquisition. To remove excess CDP-Star solution, one comer of the array membrane 
was held by forceps and the opposite membrane comer was in contact with a piece of 
clean, absorbent paper. The membrane was placed between two plastic transparencies 
and image was acquired on a Super RX film (Fuji). 
h) Micro arrays: After obtaining exposures, the damp membrane was returned back to its 
original plastic disposable hybridization tube. The cap was placed hand-tight and 
stored at -20°C. 
2.3.10 Data analysis 
Image, data and statistical analysis were performed with GEArray® Expression 
Analysis Suite Package. After logging into the site, http://geasuite.superarray.com/, 
project name was created and Array image was uploaded to each project. Images were 
optimized and adjusted to the crop frame in the Image Setting Workplace. Then 
workplace was switched to Grid/Readout where circles on the grid were aligned to the 
spots on the image. When the position and size of the spots were adjusted, readout was 
built and saved. Once readouts were available for all arrays, analysis was done to Arrays 
in two groups and gene names and their expressions were listed. A Scatter plot was 
obtained from all Arrays in one group and fold changes in gene expression between 
groups were calculated. 
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Materials & Methods ~ In vivo 
Andrographolide is believed to have pharmacological activity. In this part of the 
experiment, the effect of andrographolide on hepatocarcinoma in rats was investigated 
through ALT & AST assays, hematoxylin & eosin staining, immunohistochemical staining 
of GST-P, RNA expressions of p53 & mdm2 and western blot analysis of p53, mdm2, 
PCNA, Bax, Bcl-2 and p21. 
Chapter 3. Effects of andrographolide on hepatocarcinogenesis in rats 
Animal Treatment, liver perfusion, AST/ALT Assays & Stainings 
3.1 Materials & Solutions 
Chemicals & Reagents Purchasers 
ALT/SGPT (UV-Rate) & AST/SGOT (UV-Rate) Ki t sS tanb io Laboratory (Texas, USA) 
for detection of alanine and aspartate transferases 
respectively 
Diethylnitrosamine (DEN), hydrogen peroxide (30%), Sigma Chemicals (St. Louis, USA) 
diaminobenzidine (DAB), formaldehyde 36% 
Anti-GST-P polyclonal antibody (rabbit) Medical & Biological Laboratories 
Biotinylated goat anti-rabbit IgG and avidinbiotin- Santa Cruz Biotechnology (Ca., 
peroxidase complex (ABC Staining System) USA) 
Superfrost / plus microscope slide (25 x 75 x 1.0 mm), Fisher Scientific (Pittsburgh, 
DMSO (Dimethylsulfoxide) USA) 
4 5 
Glass microscope slide (25.4 x 76.2 x 1.2 mm) Sail Brand (Shanghai) 
Ethanol 100% BDH (England) 
Carbon tetrachloride (CCI4) Merck (Germany) 
Tris, sodium dodecyl sulfate (SDS), citric acid USB (Cleveland, USA) 
(trisodium dehydrate) 
Andrographolide (AND) 98% Sigma-Aldrich (USA) 
Com Oil Vecom (USA) 
3.2 Preparation of Solutions 
DEN solution (200 mg/ml): DEN solution for the initiation of rat HCC was prepared by 
diluting 2.52 ml of DEN to 12 ml with DMSO. 
CClj^solution: It was prepared by mixing CCI4 with com oil in 1:1 ratio. 
Andrographolide (10 mg/ml) solution: It was prepared by dissolving 500 mg of AND in 
50 ml of com oil. 
Tris-sucrose buffer fpH 7.4): The buffer used for liver perfusion was prepared by 
dissolving 95.6 g of sucrose and 6.06 g of Tris in 900 ml of dHiO. The pH was adjusted 
to be 7.4 with HCl and volume was made up to 1000 ml with dHiO. The solution was 
then stored at 4°C. 
Formaldehyde solution (10%): Formaldehyde buffer for the liver section fixation was 
prepared by mixing 10 ml of 36% formaldehyde with 26 ml of dHiO to make 36 ml of 
formaldehyde solution. 
1% hydrogen peroxide (H7O2): The solution was freshly prepared by diluting 3 ml of 30% 
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hydrogen peroxide with dK^O to make a final volume of 300 ml. 
Citric acid buffer (pH 6.0): It was prepared by dissolving 0.63 g of citric acid with 300 ml 
of dHiO. The pH was adjusted to 6.0 with sodium hydroxide (NaOH). 
Diluted normal serum (NS): The solution was prepared by diluting 150 [d of NS from 
ABC staining kit in 10 ml of 1 X PBS. 
Diluted anti-GST-P antibody (1:10): This primary antibody was diluted in 1:10 ratio by 
adding 0.5 ml of anti-GST-P antibody to 4.5 ml of diluted NS. 
Diluted Biotinylated goat anti-rabbit IgG (1:200): It was prepared by diluting 25 jul of 
antibody in 4.975 ml of diluted NS. 
Diluted avidinbiotin-peroxidase complex (ABC): It was prepared by mixing 100 |il of A 
and B from ABC staining kit in 4.8 ml of IX PBS. 
DAB solution: It was freshly prepared by dissolving 15 mg of DAB in 150 ml of PBS, 
with 8 i^l of 30% H2O2 added before use. 
3.3 Procedures 
3.3.1 Animal treatment 
Male Spraque Dawley rats (80-90 g of body weight) were obtained from 
Laboratory Animal Services Center of The Chinese University of Hong Kong (Hong Kong 
SAR, The People's Republic of China). They were divided into three groups (Negative 
control, Positive control and Treatment) and housed in three different cages in animal 
room maintained with a 12 hr light-dark cycle (06:00-18:00) at constant temperature and 
humidity of 55 士 S�/). They were given unlimited rodent diet (Supastok Autoclavable 
Rodent Diet, Ridley Agripoducts, Australia) and water ad libitum. Rats were observed 
47 
during the acclimatizing week and were then used for different treatments according to the 
protocols described below. 
Table 3.3.1 Treatment of rats for the promotion & progression stages of 
hepatocarcinogenesis 
i.p. injection of toxicant/ vehicle Oral treatment (once a day) 
(once a week) 
Negative Control DMSO + Com Oil Com Oil 
Positive Control DEN + CCI4 Com Oil 
AND-treated DEN + CCI4 Andrographolide (10 mg/kg) 
Table 3.3.1 The treatment of rats in two stages of hepatocarcinogenesis. Rats were 
divided into three groups: negative, positive and AND-treated. The negative control group 
received i.p. injection of the vehicle, DMSO, and oral treatment of com oil. The positive 
control and AND-treated groups received i.p. injection of a tumor initiator, DEN, for the 
first two weeks and then a tumor promoter, CCI4, for the rest of the weeks. Rats in the 
positive control group were given com oil once daily whereas those in the AND-treated 
group were given 10 mg/kg of AND. 
3.3.2 Promotion (Experiment 1): 
This experiment was designed to study the effect of AND at the promotion stage of 
rat hepatocarinogenesis. Fifteen Sprague Dawley rats were equally divided into negative 
control, positive control and AND-treated groups. The negative control group received 
weekly intraperitoneal injection of DMSO (1 ml/kg of body wt) for the first two weeks, 
followed by a 5-day period of fasting for the next two weeks. Com oil (1 ml/kg of body 
wt) was then administered intraperitoneally for the rest of the weeks. On the other hand, 
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both the positive control and AND-treated groups received DEN (200 mg/kg body wt) for 
the first two weeks and then two 5-day periods of fasting. Between two weeks' of fasting, 
two days of ad libitum feeding were applied to allow maximum fasting experience with 
minimal fatalities. After the fasting periods, CCI4 was administered intraperitoneally for 
the rest of the weeks. From the week onwards, both the negative and positive controls 
received oral treatment of com oil once a day. AND (10 mg/kg of body weight) was 
administered orally to the treatment group once daily. At the end of the experiment, which 
lasted for 28 weeks, all rats were weighed and then killed by nitrogen gas. Blood samples 
were collected. The liver samples were perfused with cold Tris-sucrose buffer and then 
removed, washed and weighed. Liver slices of about 2-3 mm in thickness were cut out. 
They were fixed in 10% formaldehyde for 24 hrs and then 75% ethanol until sections were 
embedded in wax by standard procedures. The remaining part of the liver was stored at -
80°C for further analysis. 
3.3.3 Progression (Experiment 2): 
This experiment was designed to investigate the effect of AND at the progression 
stage of rat hepatocarcinogenesis. Fifteen Spraque Dawley rats were equally divided into 
negative control, positive control and AND-treated groups. The intraperitoneal treatments 
for all the groups were the same as those in experiment 1. Oral treatment with com oil (1 
ml/kg of body weight) or AND (10 mg/kg of body weight) was not given to the groups 
until the 32°d week of the experiment. At the end of the week, rats were weighed and 
killed by nitrogen gas. Blood samples were collected for further analysis. Liver samples 
were perfused and stored as described in experiment I. 
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Figure 3.3.2 Experimental protocol for rat treatments in Experiment 1 
DMSO Fasting Com Oil (i.p.) killed 
Group I l l l l l l l l l l l l l l l l l ,疆 j : : 等 : : : • : : � : : : ; : )魏 : 
d e n Fasting CCU (i.p.) 
^ •• iniiiiiiiiiiiiiiih'.. ~ ‘‘ 
Group II lllllllllllllllllll卜 ： ‘ - ‘ 
DEN Fasting cCU (i.p.) + And (oral) killed 
Group III l l l l l l l l l l l l l l l l l l , ' , � ’ ： H 
I 1 1 n 1 
2 4 28 Weeks 
Figure 3.3.2 Treatment schedule of the rat in the promotion stage of hepatocarcinogenesis. 
Group I represents the negative control rats which did not receive any toxicants. Group II 
is the positive control rats which were exposed to DEN and CCI4. Group III represents the 
AND-treated group which was not given treatment until the week of the experimental 
schedule. 
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Figure 3.3.3 Experimental protocol for rat treatments in Experiment II 
D M S O F a s t i n g C o m Oi l ( i .p . ) 
广 I 川mmiiimiii卜------~H H ’ ‘ I t 0 二 n 
Group I | | | | | | | | | | | " | | | | L : : : > \ : : ; […11 I 豪 徽 感 K 懇 
D E N F a s t i n g CCI4 ( i .p . ) k i l led 
Group II lllllllllllllllllll … ： I n n 
II III 111} 111II , \ I t-^  . -y � I �，：《� � �< 
D E N F a s t i n g C C I 4 ( i -P . ) A n d . ( o r a l ) k i l led 
Group III ||||||||||||||||_,:,:::”对 11 ‘ | _爹羅截 ' !霞 _穩 : 
I 1 1 / / 1 1 
2 4 3 2 5 6 W e e k s 
Figure 3.3.3 The schedule of the rat treatments in the progression stage of 
hepatocarcinogenesis. Group I represents the negative control rats which did not receive 
any toxicants. Group II is the positive control rats which were exposed to DEN and CCI4. 
Group III represents the AND-treated group. Oral treatments for the three groups were not 
given until the 32°d week of the experimental schedule. 
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Measurement of serum ALT and AST 
3.3.4 Extraction of blood serum 
Blood samples collected from rats were transferred to Vacutainers and were 
allowed to sit on ice for 10 min. After that, samples were centrifugated for 15 min at 
4,000 rpm. Serum was extracted and was put on ice for ALT and AST analysis. 
3.3.5 Measurement of absorbance 
Activities of ALT and AST in rat serum were measured using Stanbio GP- and 
GO- Transminase Kits. The ALT kit (Procedure No. 0930) contained 13 mmol/L of a-
ketoglutarate and 0.4 mol/L of DL-alanine. The AST kit (Procedure No. 0920) contained 
12 mmol/L of 2-oxoglutarate and 0.2 mol/L of L-aspartic acid. The reagent was 
reconstituted with 15 ml of dHiO and 1 ml of reconstituted reagent was added to cuvet and 
pre-warmed to 37°C for 3 min. Serum (0.1 ml) was added to the cuvet and was mixed 
gently by pipetting up and down several times. The content was warmed at 37°C for 
exactly 1 min. After the incubation, cuvet was placed into a spectrophotometer and was 
blanked at time zero. The absorbance was measured at 340 nm and readings were 
recorded at 30-second interval for 3 min. The amounts of ALT and AST were calculated 
as follows: 
U/L = AA/Min x Total volume 
Absorptivity Sample volume 
U / L - AA/Minx 1768 
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Histological Analysis: H&E and immunohistochemical stainings 
3.3.6 Tissue processing 
Liver slices that were fixed in 75% ethanol were embedded in wax by tissue 
processor according to standard procedures. The waxed tissue samples were trimmed until 
the whole surface of sample was exposed. Samples were cut on a microtome at 5 um thick 
and were put into a 40°C water bath for a few minutes. Then two to three sections of each 
sample were mounted on glass slides for hematoxylin and eosin (H&E) staining and on 
superfrost plus microscope slides for immunohistochemical staining, respectively. 
Slides, each containing two to three liver sections, were placed in a slide holder 
and warmed to 48°C in oven for 10 minutes. Sections were then dewaxed and rehydrated 
with xylene (5 min x 3), 100% ethanol (5 min x 3), 95% ethanol (1 min), 80% ethanol (1 
min), 70% ethanol (1 min) and water (5 min). 
3.3.7 Hematoxylin and Eosin (H&E) Staining (Nucleus & Cytoplasm) 
Glass slides containing liver samples were stained in hematoxylin for 3 min. They 
were rinsed with tap water and allowed stain to develop for 5 min. After that they were 
destained with acid alcohol for 3 sec, followed by rinsing with tap water. Sections were 
placed in Scott tap for 1 min and then rinsed briefly in tap water. Then, slides were 
stained in eosin for 4 to 5 min, followed by rinsing with tap water. Sections were 
dehydrated briefly in 70% and 80% ethanol, and then 95% ethanol for 1 min, 100% 
ethanol for 5 min for 3 times, and lastly xylene for 5 min for 3 times. Finally slides were 
mounted with coverslip and Permount. 
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3 . 3 . 8 I m m u n o h i s t o c h e m i c a l s t a i n i n g o f G S T - P 
Superfrost plus microscope slides containing two to three sections of liver samples 
were dewaxed and rehydrated as described previously. Endogenous peroxidase activities 
of liver samples were blocked in 1% H2O2 for 5 min at room temperature. Sections were 
washed in tap water for 5 min, followed by antigen retrieval in 300 ml of citric acid buffer. 
The case and the buffer were first pre-warmed in microwave for 5 min. After the slides 
were placed in the buffer, sections were further heated for another 5 min on a hot plate. 
Sections were washed in tap water for 5 min and excess water was wiped off gently 
around each section. About 150-200 |il of diluted NS was added to each section to block 
the unspecific antigens and sections were allowed to incubate for 1 hr at room temperature. 
After the excess NS was drained off from the slides, sections were covered with 150-200 
|il of anti-GST-P polyclonal antibody in 1:10 ratio and incubated overnight at 4°C inside 
moist chamber. After binding with primary antibody, sections were washed in PBS three 
times for 5 min each. About 200 |il of biotinylated goat anti-rabbit IgG diluted in 1:200 
was added to each section and incubated for 30 min at room temperature. The slides were 
washed with PBS for three changes, each for 5 min, and then covered with 200 |il of 
freshly prepared ABC for 30 min at room temperature. After washing with PBS with 
three changes for 5 min each, sections were immersed in DAB solution for approximately 
3 min, and positive areas could be visualized under microscope. Sections were washed 
with tap water for 5 min, followed by counterstaining in hematoxylin for 2 min. Then the 
slides were washed with tap water, and were briefly destained with acid alcohol for 2 sec. 
Slides were rinsed with tap water, then immersed in Scott tap for about 30 sec, and again 
rinsed with tap water. The slides were briefly dehydrated in 70% and 80% ethanol, and 
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then 95% ethanol for 1 min, 100% ethanol for 5 min for 3 times, and lastly xylene for 5 
min for 3 times. Finally, slides were mounted with coverslip and Permount. 
3.3.9 Examination of liver sections 
Liver sections were examined using an Axiophot-2 Universal microscope (Zeiss) 
coupled with Spot 32 image analysis system. Sections were viewed under 5x, lOx, 20x 
and 40x magnifications and were analyzed using Image J program. 
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Chapter 4. Effects of Andrographolide on the expressions of Mdm2, p53, 
PCNA, Bax, Bcl-2 and p21 
mRNA & protein extraction from liver, RT-PCR, SDS-PAGE & Western blots 
4.1 Materials and Solutions 
Agarose, TEMED，HEPES, diethyl pyrocarbonate (DEPC), USB 
ammonium persulfate (APS), acrylamide/bis, MOPS, glycerol, 
bromophenol blue, sodium dodecyl sulfate (SDS), 5X M-MLV 
reaction buffer, M-MLV reverse transcriptase 
Chloroform, EDTA, isopropanol, formaldehyde, tris, magnesium Sigma 
chloride (MgCy, dithiothreitol (DTT), phenylmethylsulfonyl fluoride 
(PMSF), triethanolamine-HCl, beta-mercaptoethanol, deionized 
formamide, triton x-100, ethidium bromide (EB) 
Oligo dT primer, 10 mM dNTP mix, Taq polymerase, P-actin primer Invitrogen 
mix 
Trizol reagent, PGR buffer Gibco BRL 
Target gene primers Tech Dragon Ltd 
Complete 20 tablets (protease inhibitors) Roche 
Millipore Immobilon 26.5x375 cm Roll Bio-Gene tech. Ltd 
3MM Filter paper Whatman 
Tween-20 Pharmacia Biotech 
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Primary antibodies: anti-P-actin, anti-mdm2 (SMP14), anti-p53 Santa-Cruz Biotech 
(Pab246 & 421), anti-Bcl-2 (c-2), anti-Bax (5B7), anti-PCNA (pclO) Inc 
and anti-p21 mouse monoclonal 
Secondary antibody: goat anti-mouse HRP labeled antibody 
Methanol (MeOH), ethanol (EtOH) BDH 
Protein A sepharose CL-4B, ECL-Western Blotting detection reagent Amersham 
Fuji Super RX Film Fuji Photo Products 
Co. Ltd 
4.2 Preparation of solutions 
25 mM MgCh： It was prepared by dissolving 0.119 g of MgCl2 in 50 ml of d H2O. 
Solution A for nuclear protein extraction: The solution contained buffer A and 1 mM of 
PMSF. 
Buffer A: It was prepared by dissolving 438.3 mg ofNaCl, 119.15 mg of HEPES, 18.61 
mg of EDTA Na! 2H2O, and 0.3 g of Triton X-100 in 40 ml of water. The pH was 
adjusted to 7.9 with 1 M NaOH. The solution was made up to 50 ml of water, and then 
stored at 4°C. 
PMSF solution r200mM): It was prepared by dissolving 348.4 mg of PMSF in 10 ml of 
isopropanol, and it was stored at -20°C. 
Solution B for nuclear protein extraction: The solution contained 50 ml of Buffer B, 250 |li1 
of PMSF, 50 }il of DTT and one complete tablet. 
Buffer B: It was prepared by dissolving 238.3 mg of HEPES, 1227.2 mg ofNaCl, 5.712 
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mg of MgC12, 3.722 mg of EDTA Na! 2H2O，in 35 ml of water. The pH was adjusted to 
7.9 with NaOH, and then 12.5 ml of glycerol was added. The solution was made up to a 
final volume of 50 ml with dHiO and stored at 4°C. 
1 M DTT stock solution: DTT (1.5424 g) was dissolved in 10 ml of water and stored at -
20°C. 
Solution C for whole cell lysate: It contained 50 ml of solution C, 250 |LII P M S F , 62.5 jul 
DTT and one complete tablet. 
Buffer C: It was prepared by dissolving 238.3 g of HEPES，1227.2 mg of NaCl, 5.712 mg 
of MgCl2, 3.722 mg of EDTA Na2 2H2O in 35 ml of water. The pH was adjusted to 7.9 
with NaOH. Then 0.3 g of Triton X-100 and 12.5 ml of glycerol were added. The 
solution was made up to 50 ml of water and stored at 4°C. 
Immunoprecipitation (IP) buffer: It contained 20 mM triethanolamine-HCl, 0.7 M NaCl, 
0.5% (v/v) Nonidet P-40, 4.6 mM sodium deoxycholate, 1 mM PMSF, and one complete 
protease inhibitor tablet. The buffer was adjusted to 7.8 with HCl. 
Borate buffer: It contained 0.1 M boric acid, 0.1% (v/v) Nonidet P-40, 3.1 mM sodium 
azide. The pH was adjusted to8.0 with NaOH. 
2 X SDS sample loading buffer: The buffer contained 2.5 ml of Tris HCl (IM，pH 6.8), 10 
ml of 10% SDS, 0.00625 g of bromophenol blue, 5 ml of glycerol and 2.5 ml of beta-
mercaptoethanol (14.4 M) in dHiO to a final volume of 25 ml. 
1 M Tris-HCl (pH 8.8V. It contained 12.114 g of Tris in 80 ml of dHjO. The pH was 
adjusted to 8.8 with HCl. The solution was made up to 100 ml with dHiO. 
1.5 M Tris-HCl (6.8): It was prepared by dissolving 18.171 g of Tris in 60 ml of dE^O, 
and pH was adjusted to 6.8 with HCl. The solution was made up to 100 ml with dH20. 
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10% SDS: It contained 10 g of SDS in 100 ml of dHzO. 
30% Acrylamide/Bis: It was prepared by mixing 29 g of acrylamide and 1 g of bis-
acrylamide in 100 ml of dHzO. 
10% ammonium persulfate: It contained 0.1 g of ammonium persulfate in 1 ml of dHzO. 
1 X running buffer: The buffer contained 3.02 g of Tris-base, 18.8 g of glycine and 10 ml 
of 10% SDS in 990 ml of cfflbO. 
Transfer buffer: It contained 200 ml of MeOH, 2.93 g of glycine, 5.82 g of Tris and 3.75 
ml of 10% SDS in 796.25 ml ofdHiO. 
Tris-buffered saline/Tween (TEST) buffer: It was made up of 10 mmol of Tris-HCl (pH 
7.5), 150 mmol NaCl and 0.1% Tween-20. 
Blocking solution (5%): The blocking solution was prepared by dissolving 0.2 g of non-fat 
milk in 4 ml IX TEST. 
4.3 Procedures 
Semi-Quantitative RT-PCR Analysis of mRNA expression 
4.3.1 Total mRNA extraction from liver 
The liver tissue (25 to 50 mg) was homogenized with 0.5 ml of Trizol reagent. 
The extraction of mRNA was performed as described in sections 2.3.2 to 2.3.4. 
4.3.2 Reverse transcription of mRNA to cDNA 
It was done by mixing 3 [ig of RNA, 0.4 |il of oligo dT primer and autoclaved 
dHiO to a final volume of 14 |il. Then the solution was incubated at 70°C for 10 min. 
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After that, 1 |il of dNTP, 4 fil of M-MLV reaction buffer and 1 jil of M-MLV reverse 
transcriptase were added to the solution to make a final volume of 20 |ul The reverse 
transcription was carried out at 42°C for 50 min in a Perkin-Elmer GeneAmp® PGR 
system 9700. Samples were denatured for 15 min at 70°C and then cooled on ice. 
4.3.3 Protocol for polymerase chain reaction (PGR) 
The PGR reactions were performed in a final volume of 20 |LI1 in a GeneAmp® PCR 
system 9700. Each PCR reaction contained 1 |il of cDNA (synthesized from 4.3.2), 2 \x\ of 
PCR buffer, 1.2 of MgCb, 1 [i\ of primer mix, 0.2 of Taq polymerase, 0.4 i^l dNTP 
and 14.2 |il autoclaved dHzO to a final volume of 20 jil. The PCR mixture was incubated 
at 94°C for 5 min followed by 30 to 35 cycles of amplification. The number of cycles of 
each gene was determined from a series of PCR reactions with different cycle numbers. 
For p-actin and mdm2, each of the 30 cycles consisted of 45 sec of denaturation at 94°C, 
45 sec of annealing at 55°C and 30 sec of extension at 72°C. For p53, 35 cycles were 
performed and each cycle consisted of 45 sec of denaturation at 94°C, 45 sec of annealing 
at 58°C and 90 sec of extension at 72°C. When all cycles had been completed, a final 
extension step of 72°C for 10 min was performed. 
Table 4.3.3 Primer Sequences for RT-PCR 
Primer Name Orientation 5，Primer sequence 3' 
p53-F Forward GTGG ATCC TGAA GACT GGAT AACT GTC 
p53-R Reverse AGTC GACA GGAT GCAG AGGC TG 
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Mdm2-F Forward GTCT CTGG ACTC GGAA GATT AC 
Mdm2-R Reverse AAAC AATG CTGC TGGA AGTC G 
P-actin-F Forward ACA CCT CAA ACC ACT CCC AG 
P-actin-R Reverse AAC TCC TAA GGG GAG GAT GG 
4.3.4 DNA Gel Electrophoresis 
The PCR products were ready for gel electrophoresis which was performed as 
described in section 1.3.5. 
Analysis of Protein expressions 
4.3.5 Nuclear protein extraction 
The nuclear protein extraction was performed by homogenizing 300 mg of liver 
tissue in 0.9 ml of solution A (buffer A and 125 |il of 200 mM PMSF stock solution) on 
ice. The mixture was subsequently transferred to a microcentrifuge tube and centrifuged 
for 30 sec at 2,000 rpm at 4°C to get rid of any unbroken tissue. After that, the 
supernatant was incubated for 5 min on ice and centrifuged for 5 min at 5,000 rpm at 4°C. 
The supernatant was discarded and the pellet was resuspended in solution B and incubated 
on ice for 20 min for high-salt extraction. The lysed nuclei were transferred to a new 
microcentrifuge tube and centrifuged at 12,000 rpm for 30 sec to pellet the cellular debris. 
The supernatant was transferred to another microcentriflige tube and was stored at -20°C 
for the detection of p53 and mdm2. 
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4.3.6 Cytosolic protein extraction 
A 300 mg of liver samples were homogenized on ice in 0.9 ml of solution C and 
then centrifuged at 13,000 rpm for 5 min at 4°C. The supernatant was stored at -20°C for 
the detection of expression of Bax, Bcl-2, p21 and PCNA. 
4.3.7 Determination of protein concentration 
The protein concentration was determined by spectrophotometry at 280 run. After 
correcting the protein concentration with the dilution factor, 2 X SDS-PAGE sample 
loading buffer was added to adjust the protein concentration to 100 mg/ml. Samples were 
boiled for 5 minutes, mixed by vortexing and spinned down. 
4.3.8 Immunoprecipitation of p53 from liver nuclear protein 
For immunoprecipitation, the protein A-sepharose beads were first activated by 
suspending 1 g of dry beads in 4 ml of borate buffer and mixing for 1 hr. The borate 
buffer was centrifuged for 15 sec at 15,000 g and it was removed. The beads were 
resuspended in borate buffer to obtain 50% (v/v) suspension, and stored at 4 °C. 
The wild type anti-p53 (Pab 246) monoclonal antibody (2 jiig), dHiO (100 [il), 
nuclear protein (200 }xg), and 2 X IP buffer (100 pi) were added to a microcentrifuge tube 
and incubated for 1 hr with agitation at 4°C. The goat anti-mouse IgG antibody (5 jLig) 
was added and the solution was further incubated for another 30 min. Then, 50% protein 
A-sepharose beads (50 jil) were added and incubated for 30 min at 4°C with agitation. 
The protein A-sepharose beads were recovered by centrifligatioin (15 sec at 15,000 g) and 
washed with IP buffer by centrifugation (15 sec at 15, 000 g) and resuspended in 400 )il of 
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IP buffer. The pellet was resuspended in 30 of 2 X SDS-PAGE sample loading buffer 
and was loaded onto an SDS-PAGE gel for electrophoresis separation after boiling. 
4.3.9 Protein gel electrophoresis by SDS-PAGE 
The electrophoresis system, Mini-PROTEAN® II cell from Bio-Rad, was used for 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). A gel casting 
mould was assembled and tested with dHiO for leakage. The resolving gel solution (10%) 
was set and poured into the gel casting form. The top of the gel was layered with dHzO 
and the gel was allowed to polymerize for about 30 min. Water was discarded and 
stacking gel solution (4%) was poured on top of the resolving gel. A 10-tooth comb was 
inserted and the gel was allowed to polymerize for another 30 min. Samples mixed with 2 
X sample loading dye were boiled at 95°C for 5 min. After samples were loaded into the 
wells, the gel was run at constant voltage at 150 V for 1 hr in 1 X running buffer. 
Table 4.3.9 Components of resolving and stacking gels in SDS-PAGE 
Resolving gel 10% (1 g e l ) S t a c k i n g gel 3% (1 g e l ) ^ 
dHiO 3.6 ml 2.55 ml 
"Tris 2.25 ml (1 M，pH 8.8) 0.48 ml (1.5 M, pH 6.8) 
30% Acrylamide/Bis 2.96 ml 0.68 ml 
10% SDS 37.5 
10% (w/v) AP THii 37.5 i^l 
TEMED 3.5 3.75 
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4.3.10 Western blotting 
After SDS-PAGE was completed, the gel was removed and immersed into transfer 
buffer. Whatman 3 MM paper (6 pieces per gel) and PVDF membrane were cut into the 
same dimension as the resolving gel. Before transfer, the PVDF membrane was rinsed 
briefly with 100% MeOH for around 1 min and then immersed into transfer buffer. The 6 
pieces of Whatman papers were also soaked into transfer buffer before use. Semi-dry 
Trans-Blot electroblotter (Bio-Rad) was used for the protein transfer. A gel sandwich was 
assembled with the PVDF membrane and the resolving gel layered between two stacks of 
3 Whatman papers. Proteins were transferred to the membrane at constant voltage at 10 V 
for 1.5 hr. 
When the transfer was completed, the sandwich was disassembled and the 
membrane was rinsed briefly with TEST buffer. The membrane was immersed into 
blocking solution with primary antibody for 16 hr at 4°C with continuous agitation. The 
primary antibody used was mouse monoclonal anti-p53 (1:1,000), anti-mdm2 (1:500), 
anti-p21 (1:500), anti-Bcl-2 (1:500), anti-Bax (1:500) and anti-p-actin (1:5,000). The 
unbound primary antibody was washed away with TEST for 15 min. After three washings, 
the membrane was immersed into secondary antibody for 1 hr at room temperature with 
slow agitation. The secondary antibody used was goat anti-mouse HRP labeled antibody 
and was diluted in 1:10,000 with blocking solution. The excess antibody was washed 
away with TEST three times (15 min each). ECL-Western Blotting detection reagents 
(0.5 ml of each reagent) were mixed together and were applied to the membrane for 3 to 5 
min. After removing excess reagent, protein bands on the membrane were visualized and 
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recorded on a Super RX film (Fuji). Intensities of the bands were analyzed using Image J 
program. 
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Results - In vitro 
Chapter 1: Effects of andrographolide on Cell Viability and Cell Cycle 
The effect of andrographol ide on cell cycle was investigated. Neutral red assays 
were per formed to obtain the IC50 of cells treated with different concentrat ions of A N D for 
24, 48 and 72 hrs. Treatment of HepG2, the human liver cancer cells, with different 
concentrat ions of A N D (0 to 100 fiM) showed that A N D could inhibit cell viability by 
50% with concentrat ions 17.5，16 and 17 fiM with respect to 24, 48 and 72 hrs of 
incubation (Fig. 1.1). The effect of A N D on normal liver cells was also investigated. 
W R L 68, the human normal liver cell line, was found to be inhibited by 50% with 57, 30 
and 35 | iM of A N D incubated for 24, 48 and 72 hrs respectively (Fig. 1.2). The ICso for 
Clone 9, the rat normal liver cells, was 22 at 24 hrs, 18 at 48 hrs and 18 |iiM at 72 hrs of 
incubation (Fig. 1.3). The IC50 determined for HepG2 cells for all three t ime periods were 
significantly lower than those determined for W R L 68 cells (P < 0.05). 
Flow cytometry was performed to study the cell cycle of HepG2 upon treatment of 
AND. The D N A profiles of HepG2 cells treated with 1% D M S O as the control and 20 
and 25 | iM A N D for 24 hrs were shown in Fig. 1.4. The number of cells counted was 
10,000 and the population of cells suspended in each phase of the cell cycle was shown in 
percentage (Fig. 1.5). Upon treatment of A N D , more cells were suspended in sub Gi 
phase than those treated with D M S O only. There were no significant changes in the 
population of cells suspended in Gq/Gi, S and G2/M phases between AND-treated cells 
and control cells ( P > 0.05). The D N A profiles obtained from PI staining of HepG2 cells 
treated with 1% D M S O and 12.5 and 25 |llM of A N D for 48 hrs were shown in Fig. 1.6. 
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Treatment of A N D significantly induced the accumulation of cells in the sub Gi and Gq/G i 
phases of the cell cycle when compared with the control cells (Fig. 1.7). The populations 
of cells suspended in S and G2/M phases were also significantly decreased when compared 
with those in the control group (P < 0.05). The results suggest that AND-treated cells 
were unable to progress from the Gq/G i phase to the S phase. They arrested cell cycle 
progression in the Gq/G i phase, causing cell death through apoptosis. 
A hallmark feature of apoptosis was the observation that nuclear DNA extracted 
f rom apoptotic cells was often degraded (86). Therefore, to further confirm the 
mechanism through which A N D caused cell death, DNA was extracted from HepG2 cells 
treated with 12.5, 20, 25 and 50 |liM AND for 72 hrs. DNA was analyzed using agarose 
gel electrophoresis and fragmentation at around 200 bp was detected in cells treated with 




Figure 1.2 Cell viability of WRL 68 treated with AND for 24, 48 & 72 hrs. 
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Figure 1.2 The same treatments as shown in Fig . 1. 1 were performed with WRL 68, the 
hu man norm al li ver embryo ce ll s. Neutral red assays were performed and rc,o was 
determi ned for each incubati on time period. 
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F i g u r e 1 . 3 C e l l v i a b i l i t y o f C l o n e 9 t r e a t e d w i t h A N D f o r 2 4 , 4 8 & 7 2 h r s . 
Treatments of Clone 9 Cells with Andrographolide for 24，48 & 72hrs 
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F i g u r e 1 .3 Similar treatments were performed with Clone 9, the rat normal liver cells. 
Neutral red assays were performed and IC50 was recorded for each incubation time period. 
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F i g u r e 1 . 4 D N A p r o f i l e s o f H e p G 2 c e l l s t r e a t e d w i t h D M S O a n d A N D f o r 2 4 h r s 
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I . • iitiM 
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F igure 1.4 DNA profiles of HepG2 cells treated with DMSO and AND for 24 hrs. 
HepG2 cells incubated with A) 1% DMSO, B) 20 |iM and C) 25 jiiM of AND for 24 hrs 
were stained with PI. The DNA profiles were obtained using FACScan flow cy to meter 
and analyzed using FCS Express (V2) software. The area of the profile (in red) represents 
the total number of cells counted. 
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F i g u r e 1 . 5 A n a l y s i s o f t h e c e l l c y c l e u p o n t r e a t m e n t o f H e p G 2 w i t h D M S O a n d A N D 
f o r 2 4 h r s 
Analysis of phases of cell cycle 
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0% t d 1= 
Control 20uM 25uM 
S a m p l e S u b G i G o / G , S G V M 
Control 2.9% ± 0 . 3 66.7% ± 1 . 7 12.3% ± 1 . 5 18.4% ± 1 . 4 
20 u M (57.4% ± 1 . 3 11.�]% ± 0 . 8 ± 1 . 1 
25 ^iM 3.4% ± 0 . 2 66.3% ± 1 . 6 14.0% ± 0 . 6 16.7% ± 1 . 0 
F i g u r e 1.5 After P I staining, 10,000 HepG2 cells were counted on FACScan flow 
cytometer and the number of cells suspended in each phase of the cell cycle (sub G | . 
Gq/G], S and G2/M) was represented in percentage. The data represent mean 土 SD (// = 2). 
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Figure 1.6 DNA profiles of HepG2 cells treated with DMSO and AND for 48 hrs 
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Figure 1.6 After PI staining, the DNA profiles of HepG2 cells incubated with A) 1% 
DMSO, B) 12.5 laM and C) 25 |uM of AND for 48 hrs were obtained using FACScan flow 
cytometer and analyzed using FCS Express (V2) software. 
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F i g u r e 1 , 7 A n a l y s i s o f t h e c e l l c y c l e u p o n t r e a t m e n t o f H e p G 2 w i t h D M S O a n d A N D 
f o r 4 8 h r s 
Treatment of HepG2 with Andrographolide for 
48hrs 
1 0 0 % —— f J 
n — ] 
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• Sub G1 
20% — 
07� LZJ —— —— 
Control 12 .5uM 2 5 u M 
S a m p l e S u b G I G q / G i S G 2 / M 
Control 6.1% ± 0 . 5 62.1% ± 0 . 8 15.1% ± 0 . 8 16.7% ± 1 . 5 
12.5 ^iM 14.5% ± 0 . 8 65.4% ± 0 . 6 9.7% ± 0.5 9 .8% ± U 
25 ^iM 13.1% ± 0 . 6 67.1% ± 0 . 8 9/7% ± 0 . 7 10.4% ± 0 . 7 
F i g u r e 1.7 Analysis of cell cycle upon treatment of D M S O and A N D for 48 hrs. HepG2 
cells (10,000) were counted on FACScan flow cytometer after P I staining. The number of 
cells suspended in sub GI, Gq/G i , S and G2/M was recorded and represented in percentage. 
All data are expressed as mean 土 SD (/? = 2). Significance was found between control and 
the cells treated with 12.5 or 25 |aM A N D in all phases of cell cycle {p < 0.05). 
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F i g u r e 1 . 8 F r a g m e n t a t i o n o f D N A i n H e p G 2 c e l l s a f t e r A N D t r e a t m e n t 
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F i g u r e 1.8 At 72 hrs after treatment of HepG2 cells with DMSO or 12.5, 20, 25 and 50 
|iM of AND, DNA was extracted. Fragmented DNA was observed in cells incubated with 
50 )iM of AND. 
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Chapter 2: Effects of Andrographolide on gene expressions 
In an attempt to evaluate the toxicological aspect of AND, cDNA microarray 
analysis associated with human toxicology and drug metabolism was performed. This 
microarray generated the expression profiles of 263 genes related to the metabolic 
processes of cell stress, cell toxicity, drug resistance, and drug metabolism. 
A scatter plot was generated from the arrays of the control and AND-treated 
groups (Fig. 2.1). The up-regulated genes included those whose expression level is critical 
in drug metabolism such as NAD(P)H dehydrogenase quinone 1 (NQOl), superoxide 
dismutase 1 (SODl), thymidylate synthetase (TYMS) and xanthine dehydrogenase (XDH). 
Other up-regulated genes also included those that are involved in cell cycle regulation 
such as RBI . 
The down-regulated genes included a number of apoptotic and cell cycle regulators 
such as BCL2, BCL2L2, and CHEK2. Many genes whose expression level is important to 
drug metabolism such as CYP 2D6 and CYP 2A6 were also down-regulated. Some genes 
related to cell growth, proliferation and differentiation were under-expressed. They 
included ILIB and NFKB2 (Fig. 2.2). 
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F i g u r e 2 . 1 T h e s c a t t e r p l o t o f g e n e e x p r e s s i o n s f r o m H e p G 2 c e l l s t r e a t e d w i t h D M S O 
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F i g u r e 2 . 1 The scatter plot of gene expressions of HepG2 cells treated with D M S O and 
AND. Each symbol represented one gene. The center line indicates no changes in gene 
expression. Parallel lines represent the boundary which was set to be 3. The black 
symbols indicate the genes of which expression changes were less than the boundary. Red 
symbols indicate an increase in gene expression from X axis to Y axis greater than the 
boundary. Green symbols indicate a decrease in gene expression f rom X axis to Y axis 
greater than the boundary. 
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Figure 2,2 cDNA microarray analysis 
A mm B «• • • • 




• 鼸 • 
# ft i» t 
_ • ，： f 
m • ， 
« A • _ 
i • t 
C S y m b o l G e n e n a m e F o l d c h a n g e s 
BCL2 Bcl-2 -4:9 
BCL2L2 Bcl-w -3.2 
C C N D l Cyc l inDl -3.6 
CHEK2 CHK2 -4.3 
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SODl Cu/ZnSOD +3.1 
F i g u r e 2 .2 cDNA microaray analysis of A) DMSO control and B) AND-treated cells. C) 
Upon treatment of 16 |LIM of AND for 48 hrs, six genes were up-regulated 3-folds or more 
than the control; forty-two genes were down-regulated 3-folds or more and some of them 
were listed above. 
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Results - In vivo 
Chapter 3: Effects of Andrographolide on hepatocarcinogenesis in rats 
In this part of the experiment, the promotion and progression stages of 
hepatocarcinogenesis were investigated. The combined effects of DEN and CCI4 was 
observed after 5 months of treatment. Gross examination of the liver showed that the liver 
had expanded from the right to the left side of the rat's abdomen (Fig. 3.1 A). A closer 
look of the liver showed that there had been a change in morphology and nodules were 
observed across the liver surface (Fig. 3.IB). In the promotion experiment, the livers of 
the negative control group generally had a smooth surface and neither nodules nor lipids 
could be observed on the surface. On the other hand, the positive control livers had a 
thickened border and the surface was rough with lipid droplets distributing throughout the 
whole surface. The AND-treated livers had a smooth surface and generally resembled the 
negative control livers (Fig. 3.2). In the progression experiment, no abnormal appearance 
of the rat liver was found in negative control group. However, it was observed that rat 
livers were hardened and nodules or lumps were present in positive control group. There 
were also some nodules present on the surface of the AND-treated livers, but the structure 
of the livers generally resembled that of the normal livers (Fig. 3.3). 
The relative liver weights of rats from the negative, positive and AND-treated 
groups in both experiments were compared (Fig. 3.4). There was a significant increase in 
the relative liver weights in positive control groups as compared with those of rats in 
negative control groups. A significant reduction in the relative liver weights was found in 
the AND-treated groups in both experiments. No significant difference was observed in 
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AND-treated groups when compared with negative control groups in both experiments 
(Fig. 3.4). 
Serum AST and ALT activities were measured to assess liver damage. The 
percentage changes of serum AST and ALT levels relative to negative control were 
summarized in Fig. 3.5. In both experiments, values for serum AST and ALT levels in 
rats of positive control group were elevated as compared with those in negative control 
group. There was a significant reduction in AST and ALT levels in rats that had treated 
with AND (Fig. 3.5A for promotion experiment, p < 0.01; Fig. 3.5B for progression 
experiment, p < 0.05). These data suggest that AND is effective in decreasing serum AST 
and ALT levels. 
Histological examination of livers from rats in the promotion stage of 
hepatocarcinogenesis was carried out through Hematoxylin & Eosin (H & E) staining. 
The nuclei of hepatocytes were stained blue due to the color of hematoxylin and the 
cytoplasm was stained red due to eosin. The liver section of a negative control rat had a 
typical histological structure with a characteristic pattern of hexagonal lobules. The 
central vein was clearly observed and hepatocytes surrounding the central vein were 
arranged in columns, radiating from it (Fig. 3.6A, B). It was shown that after treatment of 
carcinogens, normal hepatocyte alignment was disrupted and cytoplasmic vacuolization 
within hepatocytes could be observed (Fig. 3.6C). The conditions were improved in those 
livers obtained from AND-treated rats. Liver structure was restored and hepatocyte 
arrangement was not as distorted as that of the positive control sections. Vacuolization 
was reduced and distinct cytoplasm was visible (Fig. 3.6D). In the progression experiment, 
the structural appearance of the negative control section was similar to that in the 
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promotion group (Fig. 3.7A). The liver section of the rat treated with AND also showed 
normal alignment of hepatocytes around central vein (Fig. 3.7B). The positive control 
sections, on the other hand, showed that hepatocytes were arranged randomly across the 
whole section and distinct cytoplasm could not be observed (Fig. 3.7C, D). 
Immunohistochemical staining of GST-P foci was performed to detect the presence 
of neoplastic cells. Negative control rats in the promotion stages of hepatocarcinogenesis 
did not develop any GST-P positive liver foci (Fig. 3.8A, B). In carcinogen treated groups, 
GST-P foci were detected (Fig. 3.8C, D). The expression of GST-P was found in clusters 
or groups and they could be found across the whole liver section. In the AND-treated liver 
section, the expression of GST-P was present but the affected area was reduced (Fig. 3.8E, 
F). In the progression group, GST-P foci could not be detected in the normal rat liver 
sections (Fig. 3.9A). The rats in the positive control groups showed clusters of GST-P 
foci (Fig. 3.9B). A closer look at these sections showed cytoplasmic vacuolization and 
abnormal alignment of hepatocytes (Fig. 3.9C). In some areas of the positive control 
section where expression of GST-P was not detected, hepatocytes were aligned randomly 
and no distinct cytoplasm was present (Fig. 3.9D). The AND-treated liver sections were 
similar to the negative control sections with distinct central vein and normal hepatocyte 
appearance (Fig. 3.9E, F). 
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F i g u r e 3 . 1 E f f e c t s o f d i e t h y l n i t r o s a m i n e ( D E N ) a n d c a r b o n t e t r a c h l o r i d e (CCI4) o n 
r a t l i v e r 
A ^ ^ ^ 
B n ^ y i ' 
F i g u r e 3 .1 A) The rat was treated with DEN & C C U once a week for about 5 months; B) 
The rat 's liver was removed and many nodules as indicated by the arrows was observed 
across the surface of the liver. 
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F i g u r e 3 . 2 G r o s s e x a m i n a t i o n o f r a t l i v e r s i n t h e p r o m o t i o n s t a g e o f 
h e p a t o c a r c i n o g e n e s i s 
F i g u r e 3 .2 After 28 weeks, rats were killed and their livers were perfused, removed & 
weighed. Liver removed from A) a normal control rat; B) AND-treated rat and C) 
positive control rat. Nodules or lumps as indicated by the arrows could be seen across the 
surface of the positive control liver. 
83 
Figure 3 3 Gross examination of rat livers in the progression stage of 
hepatocarcinogenesis 
Figure 3.3 At the end of 56 '^' week, rats were killed and their livers were examined. A) 
Negative control liver; B) AND-treated liver and C) positive control liver. 
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F i g u r e 3 . 4 E f f e c t s o f A N D o n t h e l i v e r w e i g h t o f r a t s i n p r o m o t i o n a n d p r o g r e s s i o n 
g r o u p s 
A Effects of AND on the liver weight of rats in 
promotion group 
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F i g u r e 3 . 4 The relative liver weight was expressed as percentage (liver weight/ body 
weight). The data represent the mean of 5 rats. There was a significant difference 
between positive control and the AND-treated groups in both the promotion and 
progression {？ < 0.05). 
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F i g u r e 3.5 A S T a n d A L T a s s a y s f o r t h e p r o m o t i o n a n d p r o g r e s s i o n g r o u p s o f r a t s 
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Figure 3.5 AST and ALT assays for the A) promotion and B) progression groups of rats. 
The amount of AST and ALT in blood serum was measured and represent the percentage 
compared with the negative control. Significance was found between the positive control 
and AND-treated rats in both the promotion and progression groups {P < 0.05). 
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F i g u r e 3 . 6 H e m a t o x y l i n & E o s i n ( H & E ) s t a i n i n g o f r a t l i v e r s i n t h e p r o m o t i o n s t a g e 
o f h e p a t o c a r c i n o g e n e s i s 
麗 ' M 
驪麗 
F i g u r e 3.6 The nuclei of the hepatocytes were stained blue and the cytoplasm was stained 
red. A) The liver section (lOX) of a negative control rat. B) Magnification of the square 
area in section A (20X). C) Positive control liver sections (20X) and D) AND-treated 
liver section (20X). 
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Figure 3 7 & Eosin (H&E) staining of rat livers in the progression 
‘ . stage of hepatocarcinogenesis 
瞧讀 mm ^m 
驪 驪 
Figure 3.7 A) The liver section of a negative control rat (20X). B) The liver section of a 
rat treated with AND (20X). C) Positive control sections with no distinct cytoplasm (lOX) 
and D) hepatocytes were arranged randomly across the whole section (20X). 
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Figure 3.8 Immunostaining of GST-P of rat liver sections in the promotion group 
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Figure 3.8 The nuclei of the hepatocytes were stained blue and the areas with GST-P 
expression were stained brown. A) Negative control section showed no expression of 
GST-P (lOX). B) Magnification of the section in A (20X). C) Liver section from a 
positive control rat (lOX). D) Magnification of the section in C (20X). E) Liver section 
obtained from AND-treated liver (lOX) and F) the magnified area from section E (20X). 
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F i g u r e 3 . 9 A) The negative control sections with distinct central vein (20X). B) Positive 
control section showed expressions of GST-P in groups (lOX). C) Positive control 
section showed the appearance of hepatocytes (20X). D) Positive control section with no 
GST-P expression (20X). E) The AND-treated liver sections (1 OX). F) The magnified 
area in section E (20X). 
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Chapter 4. Effects of Andrographolide on the expressions of Mdin2, p53, 
PCNA, Bax, Bcl-2 and p21 
To study the effect of AND on the inhibition of hepatocarcinogenesis in both the 
promotion and progression stages, Western blot of PCNA, a marker of cell proliferation 
was done (Fig. 4.1). The level of PCNA expression in DEN-CCU treated rat was found to 
be significantly higher than that in the negative control and AND-treated groups in the 
progression experiment. However, there was no significant difference in the levels of 
PCNA expression in the AND-treated and positive control groups in the promotion 
experiment. 
To determine the effect of AND on cells associated with apoptosis, the protein 
expressions of Bax and Bcl-2 were investigated by Western blot analysis (Fig. 4.3). In 
both experiments, the levels of Bax protein expressed in the liver of rats which received 
carcinogens were significantly lower than those rats which received vehicle or AND 
treatment. The levels of Bcl-2 in the liver of carcinogen-treated rats in the positive control 
groups were higher than that in the control or AND-treated groups. These data suggest 
that AND had triggered a reduction of Bax expression but an increase in Bcl-2 expression. 
The effects of AND on cell cycle regulation were investigated through the Western 
blot analysis of p21 (Wafl/Cipl/Sdil), which functions at major transition points in the 
cell cycle. In both the promotion and progression experiments, the levels of p21 
(Wafl/Cipl/Sdil) in carcinogen-treated groups were lower than those in the negative 
control and AND-treated groups. However, no significant difference could be observed 
among the three groups (Fig. 4.4). 
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The total p53 protein (wild type and mutant) expressions in rat liver nuclei were 
measured (Fig. 4.5). When compared with the negative control groups, higher levels of 
total p53 protein expression were found in rats treated with DEN-CC14 alone in the 
positive control groups and the AND-treated groups in both the promotion and progression 
experiments. However, no significant difference was observed among these groups. The 
wild type p53 functions in cell cycle arrest and in triggering the apoptotic event. The 
changes in the wild type p53 protein expression were determined through 
immunoprecipitation and western blot analysis (Fig. 4.6). In the promotion experiment, 
the level of wild type p53 protein expression was lower than that in the AND-treated and 
control rats. However, no significant difference was observed in these groups. In the 
progression experiment, nuclear wild type p53 was significantly reduced in the positive 
control group as compared to those in the negative or AND-treated groups. The results 
showed that administration of AND significantly increased the expression of wild type 
p53 compared with the positive control. 
The protein expression of p53 was regulated by Mdm2. In both experiments, there 
was a significant overexpression of Mdm2 in DEN-CCI4 treatment in positive control 
groups as compared with those that received the vehicle treatment. A significant decrease 
in the levels of Mdm2 was observed in AND-treated groups as compared with the positive 
control groups (Fig. 4.7). The findings suggest that treatment with AND significantly 
reduced the protein expression of Mdm2. 
The effects of AND on the inhibition of hepatocarcinogenesis were further 
investigated at the transcriptional level of total p53 and Mdm2. The transcripts encoding 
the mRNA of p53 and Mdm2 were normalized with the corresponding p- actin mRNA 
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transcripts and changes in the transcriptional level were expressed in ratio as shown in Fig. 
4.7 and Fig. 4.8. In both experiments, it was observed that the mRNA expression o fp53 
was low in the vehicle control groups. The treatment of DEN-CCI4 significantly increased 
the mRNA transcripts of p53. Upon treatment of AND, there was a significant reduction 
in the total p53 transcription expression which was brought about by the carcinogens. The 
mRNA expression of Mdm2 was also low in the vehicle-treated rats as shown in Fig. 4.9. 
There was a considerate over-expression of Mdm2 mRNA in carcinogen-treated positive 
control groups in both experiments. However, the expression of Mdm2 mRNA was 
significantly reduced in AND-treated groups when compared with that in the positive 
control groups. 
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Figure 4.6 Western blot analysis of wildtype p53 protein 
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F i g u r e 4 . 1 The cytosolic proteins in the rat liver were separated by 10% SDS-PAGE and 
transferred onto P V D F membrane. A) P C N A was detected and expressed in PCNA : p-
actin ratio. Significance was found between the AND-treated and positive control groups 
in the progression experiment (p < 0.05). All data were expressed as mean 土 SD (n = 5). 
B) P C N A expression. (3-actin was the internal standard. 
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Figure 4.2 Western blot analysis of Bax protein 
A Effects of A N D o n the level of Bax protein 
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F i g u r e 4 . 2 The cytosolic protein, Bax, in the rat liver was separated by 10% SDS-PAGE 
and transferred onto P V D F membrane. It was detected with mouse antibodies against Bax 
followed by goal ant i -mouse-HRP visualization. A) Bax was expressed in Bax : (3-aclin 
ratio. Significance was found between the AND-trcated and positive control groups in 
both experiments {p < 0.05). All data were expressed as mean 土 SD (// = 5). B) Bax 
expression, [^-actin was the internal standard. 
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Figure 4.3 The cytosolic proteins in the rat liver were separated by 10% SDS-PAGE and 
transferred onto P V D F membrane. Bcl-2 was detected with mouse antibodies against Bcl-
2 fol lowed by goat ant i -mouse-HRP visualization. A) Bcl-2 was expressed in Bcl-2 : (3-
actin ratio. Significance was found between the AND-treated and positive control groups 
in both experiments (p < 0.05). All data were expressed as mean 土 SD (n = 5). B) Bcl-2 
expression. (3-actin was the internal standard. 
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F i g u r e 4 . 4 W e s t e r n b l o t a n a l y s i s o f p 2 1 p r o t e i n 
A Effects of A N D o n the level of p21 protein 
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F i g u r e 4 . 4 The protein p21 in the rat liver was separated by 10% SDS-PAGE and 
transferred onto P V D F membrane. It was detected with mouse antibodies against p21 
fol lowed by goat ant i -mouse-HRP visualization. A) p21 was expressed in p21 : p-actin 
ratio. Levels of p21 in AND-treated groups were higher than positive control groups, but 
no significant difference was observed in both experiments. All data were expressed as 
mean 土 SD (n = 5). B) p21 expression, p-actin was the internal standard. 
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F i g u r e 4 . 5 W e s t e r n b l o t a n a l y s i s o f t o t a l p 5 3 p r o t e i n 
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F i g u r e 4 .5 Total p53 was separated by 10% SDS-PAGE and then transferred onto PVDF 
membrane. The nuclear protein was detected with mouse antibodies against p53 (Pab 421) 
and goat anti-mouse-HRP. A) Total p53 was expressed in p53 : p-actin ratio. There was 
no significant difference in the levels of total p53 in AND-treated groups as compared 
with the positive control groups in both experiments. All data were expressed as mean 土 
SD (n = 5). B) Total p53 expression. P-actin was the internal standard. 
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Figure 4.6 Western blot analysis of wildtype p53 protein 
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Figure 4.6 Nuclear proteins were irnmunoprecipitatcd with mouse monoclonal anti-p53 
antibody (Pab 246). The precipitated protein were separated and transferred onto the 
P V D F membrane. Wildtype p53 was detected with mouse antibodies against wl p53 (Pab 
421) and goal ant i -mouse-HRP. A) Wl p53 was expressed in wl. p53 : (^aclin ratio. There 
was no significant difference in the levels of wt. p53 in AND-trcated group as compared 
with that in the positive control group in the promotion experiment. In the progression 
experiment, however, a significant increase in the level of wt. p53 in AND-treated group 
was observed when compared with that in the positive control group (p < 0.05). All dam 
were expressed as mean 土 SD (/? = 5). B) Wt. p53 expression. P-actin was the internal 
standard. 
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Figure 4.6 Western blot analysis of wildtype p53 protein 
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F i g u r e 4 .7 The nuclear proteins in the rat liver were separated by 10% SDS-PAGE and 
transferred onto PVDF membrane. Mdm2 was detected with mouse antibodies against 
Mdm2 and goat anti-mouse-HRP. A) Mdm2 was expressed in Mdm2 : P-actin ratio. 
There was a significant decrease in the levels of Mdm2 in AND-treated groups as 
compared with the positive control groups in both experiments {p < 0.05). All data were 
expressed as mean 土 SD (/? = 5). B) Mdni2 expression, p-actin was the internal standard. 
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Figure 4.8 Effects of AND on the expression of v53 mRNA 
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Figure 4.8 A) p53 expression was measured as the ratio of p53 : l^-actiu. There was a 
significant reduction in the expression in the AND-treated group when compared to that in 
the positive control group in both experiments {p < 0.05). All data were expressed as 
mean 土 SD (n = 5). B) p53 mRNA expression, p-actin was the internal standard. 
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Figure 4.9 Effects of AND on the expression of Mdm2 mRNA 
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Figure 4.9 A) Mdm2 expression was measured as the ratio of Mdm2 : p-actin. There was 
a significant reduction in the expression in the AND-treated group when compared to that 
in the positive control group in both experiments {p < 0.05). All data were expressed as 
mean 土 SD {n 二 5). B) Mdm2 mRNA expression, p-actin was the internal standard. 
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Discussion 
Andrographolide (AND), the active component extracted from Andrographis 
Paniculata (AP), was reported to possess pharmacological properties. These include 
protozoacidal, anti-mutagenic and anti-carcinogenic activities (82-85). The beneficial 
effects of AND on liver, however, are not fully understood. Therefore, the present study 
was aimed at investigating the biological activities of AND on the liver through in vitro 
and in vivo studies. 
AND causes inhibition of cell growth 
Cell cycle is an ordered set of events in a eukaryotic cell from one cell division to 
the next. It is initiated in the presence of mitogenic stimulus and is normally regulated by 
cyclins and cyclin-dependent kinases (87). However, this regulation of the cell cycle is 
lost in cancer cells and they continue to divide in the presence or absence of a mitogenic 
stimulus (88). Many anti-cancer agents are known to possess the ability to block the cell 
cycle at different stages. This includes doxorubicin, an anti-cancer agent that blocks cell 
cycle at G2 phase (89). 
In the present study, AND displayed a significantly inhibitory effect on the 
proliferation of human liver cancer cell line, HepG2 (Fig. 1.1). On the other hand, the 
normal liver cells, WRL 68 and Clone 9, were less sensitive to AND, although significant 
cytotoxicity was also detectable at a concentration of 1 8 | L I M (Fig. 1 . 2 & 1 . 3 ) . The results 
imply that AND could have therapeutic potential in treatment of cancer when lower doses 
are administered to rats. 
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In addition, FACS analysis demonstrated that the HepG2 cells treated with AND 
(25 [iM) for 4 8 hrs exhibited a dramatic accumulation (67 .1%) of cells in G Q / G I phase of 
the cell cycle (Fig. 1 . 7 ) . The increase in the population of cells suspended in G Q / G I phase 
is regulated by many cell cycle proteins. The most critical determinant of the Gi arrest is 
p21 (Wafl/Cipl/Sdil) which interacts with cyclins D and E during the early Gi phase of 
the cell cycle, inhibiting the activity of cyclin D/ CDK complex (42). The inactive cyclin 
D/CDK complex leads to the inactivation of kinases which subsequently activates the 
tumor suppressor, retinoblastoma (Rb)，and that inhibits cell cycle progression through the 
Gi to S phase. Besides the important role of p21, the expression of level cyclin D1 has 
also been shown to be rate-limiting in cellular proliferation (90). Consistent with its role 
in cell cycle progression, increased expression of cyclin D1 has been detected in breast 
cancer cells (91) and colorectal carcinogenesis (92). The tumor suppressor, Rb, functions 
as an active repressor of the transcription of E2F-responsive genes that are required for the 
initiation of DNA synthesis (93). Mutations of its DNA sequence or defect in gene 
transcription can result in Rb inactivation which occurs in all retinoblastomas (94). 
Therefore, p21, cyclin D1 and Rb are important elements in governing cell cycle 
progression at Gi-S-phase transition. In the present study, although no significant 
difference was observed, a higher expression of p21 was detected in vivo by Western blots 
in livers from negative control and AND-treated rats than that from the positive control 
rats. Micro array analysis further revealed that expression of CCNDl, whose protein 
product is cyclin Dl, was down-regulated whereas RBI, whose protein product is Rb, was 
up-regulated upon treatment of AND. Another cell cycle control gene, CHEK-2, whose 
expression level is critical to cell cycle checkpoint regulation and putative tumor 
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suppression, was also found to be down-regulated. The findings show that AND can 
cause an arrest in the cell cycle at GpS phase transition in liver cells. 
AND causes apoptotic cell death 
Apoptosis is a genetically encoded form of cell suicide central to the development 
and homeostasis of multicellular organisms. Cells undergoing apoptosis display a 
characteristic pattern of structural changes in the nucleus and cytoplasm, including nuclear 
disintegration (95). The cleavage of DNA into oligonucleosomal-length fragments is a 
late event in apoptosis and it was detected in vitro in the cell cycle analysis. The treatment 
of HepG2 cells with AND (25 fiM) resulted in a significant increase in the percentage of 
cells (13.1%) suspended in the Sub GI phase of the cell cycle (Fig. 1.7). DNA 
fragmentation in HepG2 cells was further confirmed with 50 ^M of AND incubated for 72 
hrs (Fig. 1.8). 
Mitochondria have been shown to play a central role in the apoptotic process, 
because both the intrinsic pathway and the extrinsic pathway converge at the 
mitochondrial level and trigger mitochondrial membrane permeabilization (96). After 
apoptotic-stimulated mitochondrial membrane permeabilization, cytochrome c and other 
proapoptotic proteins release into the cytosol. Released cytochrome c subsequently 
triggers the activation of caspases, substrate cleavage, and cell death (97). Bcl-2, and Bax 
are the two members of the Bcl-2 family that have been implicated as major regulators in 
the control of mitochondrial cytochrome c release (97). Bcl-2 is an anti-apoptotic factor 
that binds to the outer membrane of mitochondria and blocks cytochrome c efflux. 
Conversely, upon apoptosis induction, Bax translocates from the cytosol to the 
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mitochondria where it enhances cytochrome c release through the outer membrane of 
mitochondria. Many anticancer agents or apoptotic stimuli can trigger cytochrome c 
release through either down-regulation of Bcl-2 and/or up-regulation of Bax such as 
Doxorubicin (98). In the present study, Bcl-2 protein expressions were significantly lower 
in both the negative and AND-treated rats than that in the positive control rats (Fig. 4.3). 
The protein levels of Bax were also significantly increased in the negative control and 
AND-treated groups than that in the positive control group (Fig. 4.2). Moreover, the 
micro array analysis revealed that Bcl-2 and Bcl-w, an anti-apoptotic gene, were down-
regulated in HepG2 cells treated with 16 \iU of AND for 48 hrs (Fig. 2.2). The data 
indicate that the anti-HCC effect of AND is associated with Bcl-2, Bcl-w and Bax proteins 
that trigger apoptosis. 
AND increases the stability of wild-type p53 
The tumor suppressor gene p53 is regarded as a key regulator in maintaining a 
balance between cell growth and cell death and it plays an important role in tumor growth 
inhibition and induction of apoptosis (99). The wild-type p53 mediates the expressions of 
Bax, Bcl-2 and p21 proteins. The results from in vivo study showed that wild-type p53 
expression was decreased in the liver of DEN-CCI4 treated rats，while total p53 (wild-type 
and mutant) expression was increased. It implies that the expression of mutant p53 was 
increased in the DEN-CCI4 treated rats. The major regulator of p53 turnover, Mdm2, was 
found to be over-expressed at the transcriptional level in the livers of these rats (Fig. 4.7). 
This is due to the fact that Mdm2 expression is also induced by p53 through a binding site 
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of the Mdm2 gene. Since mutant p53 cannot be degraded by Mdm2, the over-expression 
of Mdm2 leads to an increase of wild-type p53 degradation. 
The present data demonstrate a significant increase in the expression of p53 
mRNA in the positive control rats, resulting in an increase in the total p53 protein level in 
both the promotion and progression stages of carcinogenesis. On the other hand, the p53 
mRNA expression was found to decrease in the AND-treated group, and yet the total p53 
protein was increased. Since wild-type p53 protein expression was significantly increased 
in the AND-treated rats and there was a significant decrease in the expression of Mdm2 
simultaneously, the results suggest that AND down-regulates the expression of Mdm2, 
leading to an increased level of wild-type p53. It is confirmed with the microarray 
analysis, which showed a 3.4-fold changes in the down-regulation of Mdm2 expression in 
HepG2 cells treated with AND (16 |iM) for 48 hrs (Fig. 2.2C). The under-regulated 
Mdm2 gene expression reduces the protein level of Mdm2 to degrade wild-type p53, 
suggesting an increase in the stability of p53. Subsequently, the wild-type p53 can 
regulate the expressions of Bax, Bcl-2 and p21, resulting in cell cycle arrest and apoptosis 
in tumor cells. 
AND reduces liver damage caused by DEN and CCI4 
Spraque Dawley rats were treated according to established protocols in order to 
investigate the effects of AND on the promotion and progression stages of 
hepatocarcinogenesis. The initial stage of HCC can be developed in rat liver by the 
administration of diethylnitrosamine (DEN), an indirect initiator that produces DNA 
adducts. Within a few weeks, populations of initiated cells called the enzyme-altered foci 
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can be detected (100). With the administration of a promoter like CCI4, the growth of the 
initiated preneoplastic cells is enhanced. Furthermore, the two periods of fasting in the 
treatment schedule were believed to reduce the latency period for the incidence of early 
lesion during chemical carcinogenesis in rat liver (101). 
In generating a chemical carcinogenesis model in rat liver, liver cell proliferation 
plays a very important role in the whole process (102). It specifically exerts a critical 
effect in the promotion of carcinogen-initiated cells (103). Proliferating cell nuclear 
antigen (PCNA) is a co-factor for DNA polymerase 8 and is synthesized in early Gi and S 
phases of the cell cycle. It serves as a significant marker for proliferating cells and hence 
clinical malignancy. In the present study, livers from rats treated with DEN-CCI4 alone in 
both the promotion and progression experiments had a significantly higher expression of 
PCNA than those treated with vehicle. After AND treatment, the PCNA expression was 
reduced in both experiments, suggesting that liver cell proliferation was regulated upon 
AND treatment. 
AST and ALT are normally located in liver cells. When liver cells are injured, 
these two enzymes will leak out into the general circulation and cause an elevated level in 
blood serum. Hence, AST and ALT are often used as an indicator to evaluate the degree 
of liver damage. In the promotion and progression experiments, the serum levels of AST 
and ALT in AND-treated rats were significantly lower than those in the positive control 
rats (Fig. 3.5). The findings, therefore, suggest that liver damage was significantly 
reduced in rats that had been treated with AND in both the promotion and progression 
stages of hepatocarcinogenesis. 
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AND reduces the expression of GST-P foci 
Immunohistochemical identification of GST-P has been used widely for the 
detection of preneoplastic lesion in rat hepatocarcinogenesis (104). GST-P is normally 
absent in rat hepatocytes but it can be induced by various xenobiotics. It has been shown 
that GST-P mRNA is induced by lead nitrate, aflatoxin metabolites or phenobarbital (105, 
106). Several studies also reported that GST-P can be induced by epidermal growth factor 
(EGF) or insulin (107). In the present study, no GST-P foci could be detected in the 
negative control liver sections but clusters or groups of GST-P foci were extensively 
observed in the positive control sections (Fig. 3.8 & 3.9). The expression of GST-P foci in 
the DEN-CCI4 treated livers indicates the induction of preneoplastic lesions in both 
promotion and progression stages of carcinogenesis. Upon treatment of AND at a dose of 
10 mg/kg for 24 and 52 weeks, a decrease in the number and area of GST-P positive foci 
was detected at these two stages (Fig. 3.8 & 3.9). The results demonstrate that AND can 
reduce the expression of GST-P and thus the number of preneoplastic foci that were 
induced by DEN-CCI4. 
AND restores the morphology of normal liver 
Gross examination of the rat liver that had been treated with DEN-CCI4 showed the 
presence of lipid droplets, nodules and eventually tumors across the surface of the liver. 
There was also a significant increase in the relative liver weights in these rats as compared 
with those in the vehicle-treated rats. This phenomenon is typical in the treatment of CCI4 
to rats. The carcinogen induces CYP 2E1 which activates oxygen via an NADPH-
dependent mechanism (108). Subsequent dissociation of superoxide radicals from the 
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enzyme-substrate complex generates free radicals that react with microsomal membranes 
to induce lipid peroxidation that leads to cell membrane damage (109). The chronic 
administration of certain xenobiotics and the metabolizing enzymes has been reported to 
induce liver enlargement in rats (110). The increase of the relative liver weight with CCI4 
is thought to be due to liver cell proliferation called hyperplasia (111). Consistent with 
this observation, significant hyperplasia could be detected in the livers of rats that had 
been treated with DEN-CCI4 in both the promotion and progression experiments (Fig. 3.4). 
This induction of cell proliferation becomes particularly important for tumorigenesis in 
slowly proliferating tissues such as liver. 
In the promotion experiment, the AND-treated livers retained a smooth surface and 
generally resembled the negative control livers (Fig. 3.6). It was observed that some 
nodules were present in the livers that had been treated with AND in the progression stage 
(Fig. 3.7). However, the structure of the liver generally resembled that of the normal 
livers. The results reflect that AND restores the basic structure of rat livers. 
Moreover, histological examination of rat livers revealed that hepatocytes of AND-
treated livers adopted the well-defined, cuboidal shape that is characteristic of normal 
hepatocytes. Swollen hepatocytes and cytoplasmic vacuolization, which are common in 
CCI4 intoxication，were only observed in positive control sections in both experiments. 
The findings further indicate that AND can retain the normal hepatic morphology. 
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Conclusion 
Andrographolide (AND) is an active component isolated from Andrographis 
Paniculata, a Chinese herbal medicine, which possesses many biological activities (74). 
However, the beneficial effects of AND on liver have yet to be elucidated. Thus, in the 
present study, the biological activities of AND on liver was evaluated through in vitro and 
in vivo studies. 
The effect of AND on the cell cycle was demonstrated. It increased the population 
of cells suspended in G Q / G I phase, inhibiting the growth of HepG2 cells at low doses. 
Apoptotic cell death was also observed as DNA fragmentation was detected in AND-
treated cells. The changes in gene expression upon treatment of AND further indicated its 
effects on the regulation of mRNA expression of genes whose expression levels are 
critical in cell cycle and apoptosis. These genes included CCNDl, RBI, CHEK-2, BCL2, 
BCL2L2 and MDM2. 
The effects of AND on hepatocarcinogenesis induced by diethylnitrosamine (DEN) 
and carbon tetrachloride (CCI4) in Spraque Dawley rats were demonstrated. AND was 
shown to inhibit the development of HCC in the promotion and progression stages. The 
liver conditions of rats, as indicated by levels of AST/ALT in serum and PCNA protein 
expression in liver, were found to be significantly improved. Histological examination of 
AND-treated liver sections showed normal hepatic morphology. GST-P positive foci were 
also found to decrease in these sections. 
The protein expression of p53 revealed that wild-type p53 was increased and 
mutant p53 was decreased with treatment of AND. The increased wild-type p53 regulated 
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the expressions of Bax, Bcl-2 and p21, causing a decrease in Bcl-2 and an increase in Bax 
and p21. The expression of Mdm2, a protein that controls the expression of p53, was 
decreased in the AND-treated groups. It indicates the stability of wild-type p53 which 
regulates the expressions of other cell cycle and apoptotic proteins. 
The present study demonstrated the effectiveness of AND in inhibiting the growth 
of HepG2 cells and reducing HCC in rats. Through the inhibition of the apoptotic events, 
cancer cells can be killed. The mediation of p53 and other signaling proteins associated 
with cancer was a result of treatment of cells with AND, leading to an array of 
pharmacological activity. The results reflect the therapeutic benefits of AND for treatment 
of liver cancer. In the future, studies can be performed to investigate the detailed 
mechanism of AND on HCC. Modification of the chemical structure of this compound 
can be performed in order to enhance its potency and to reduce the cytotoxicity of AND in 
normal human liver cells. 
112 
References 
1. Parkin,D.M., Pisani,?. and Ferlay,J. (1999) Global cancer statistics. CA Cancer J. Clin. 
49: 33-64. 
2. El-Serag, HB, Davila, J.A., Petersen, N.J. and McGlynn K.A. (2003) The continuing 
increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann 
Intern Med. 139(10): 817-23. 
3. Marrero, J.A. (2006) Hepatocellular carcinoma. Curr. Op in Gastroenterol 22(3): 248-53. 
4. Kirk, G.D.，Lesi, O.A., Mendy, M., Akano, A.O., Sam, O., Goedert, JJ. et al. (2004) The 
Gambia liver cancer study: Infection with hepatitis B and C and the risk of hepatocellular 
carcinoma in West Africa. Hepatology. 39: 211-219. 
5. Wang, X.W., Hussain, S.P., Huo, T.I., et al (2002) Molecular pathogenesis of human 
hepatocellular carcinoma. Toxicology. 181-182: 43-7. 
6. Sakamoto, M., Hirohashi, S. and Shimosato, Y. (1991) Early stages of multistep 
hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. 
Hum Patho. 22: 172-8. 
7. Chao, Y., Li, C.P., Chau, G.Y., et al (2003) Prognostic significance of vascular 
endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with 
resectable hepatocellular carcinoma after surgery. Ann Surg Oncol. 10: 355-62. 
8. Hirohashi, S. (1991) Pathology and molecular mechanisms of multistage human 
hepatocarcinogenesis. Princess Takamatsu Symp 22: 87-93. 
9. Yuspa, S.H. and Poirier, M.C. (1988) Chemical carcinogenesis: from animal models to 
molecular models in one decade. Adv Cancer Res. 50: 25-70. 
10. Neumann, H.G. (1988) Role of extent and persistence of DNA modifications in chemical 
carcinogenesis by aromatic amines. Recent Results Cancer Res. 84: 77-89. 
11. Pitot, H.C. (1990) Altered hepatic foci: Their role in murine hepatocarcinogenesis. Annu 
Rev Pharmacol Toxicol. 30: 465-500. 
12. Bannasch, P., Haertel, T. and Su, Q. (2003) Significance of hepatic preneoplasia in risk 
identification and early detection of neoplasia. Toxicol Pathol. 31: 134-9. 
13. Ashendel, C.L. (1985) The phorbol ester receptor: a phospholipids-regulated protein 
kinase. Biochem Biophys Acta. 822: 219-242. 
14. Fishbein, L. (1979) Potential halogenated industrial carcinogenic and mutagenic 
chemicals. II. Halogenated saturated hydrocarbons. Sci Total Environ. 11(2): 163-95. 
113 
15. Loeb, L.A. and Cheng, K.C. (1990) Errors in DNA synthesis: a source of spontaneous 
mutations. Mutat Res. 238: 297-304. 
16. Lengauer, C., Kinzler，K.W. and Vogelstein, B. (1998) Genetic instabilities in human 
cancers. Nature. 396: 643-9. 
17. Haber, D. and Harlow, E. (1997) Tumor-suppressor genes: evolving definitions in the 
genomic age. Nat. Genet. 16: 320-2. 
18. Kemeny. N, Daly. J, Reichman. B, et al. (1987) Intrahepatic or systemic infusion of 
fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A 
randomized trial. Ann Intern Med. 107: 459-65. 
19. Ackerman, N.B. (1974) The blood supply of experimental liver metastases. IV. Changes 
in vascularity with increasing tumor growth. Surgery. 75: 589-96. 
20. Ensminger, W.D., Rosowsky, A., Raso, V., et al. (1978) A clinical-pharmacological 
evaluation of hepatic arterial infusions of 5-fluoro-2' -deoxyuridine and 5-fluorouracil. 
Cancer Res. 38: 3784-92. 
21. Allen-Mersh, T.G., Glover, C., Fordy, C., et al. (2000) Randomized trial of regional plus 
systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in 
treatment of colorectal liver metastases. Eur J Surg Oncol. 26: 468-73. 
22. Livraghi, T., Goldberg, S.N., Lazzaroni, S., et al. (2000) Hepatocellular carcinoma: 
Radiofrequency ablation of medium and large lesions. Radiology. 214: 761-8. 
23. Livraghi, T., Goldberg, S.N., Lazzaroni, S.，et al. (1999) Radiofrequency ablation vs. 
ethanol injection in the treatment of small hepatocellular carcinoma. Radiology. 210:655-
61. 
24. Curley, S.A., Izzo, F., Ellis, L.M., et al. (2000) Radiofrequency ablation of hepatocellular 
cancer in 110 patients with cirrhosis. Ann Surg., 232: 381-91. 
25. Sparchez, Z. and Bolog, N. (2003) Ultrasound guided percutaneous ethanol injection of 
hepatocellular carcinoma. Rom. J. Gastroenterol 12: 147-55. 
26. Llovet, J.M., Bruix, J., Fuster, J., Castells, A., Garcia-Valdecasas, J.C., Grande, L., et al. 
(1998) Liver transplantation for small hepatocellular carcinoma: The tumor-node-
metastasis classification does not have prognostic power. Hepatology. 27: 1572-77. 
27. Marsh, J.W., Dvorchik, I., Subotin, M，Balan, V., Rakela, J., Popechitelev, E.P., et al. 
(1997) The prediction of risk of recurrence and time to recurrence of hepatocellular 
carcinoma after orthotopic liver transplantation: A pilot study. Hepatology. 26: 444-50. 
28. Cox, A.D. and Der C.J. (2002) Ras family signaling: therapeutic targeting. Cancer Biol. 
Ther. 1(6): 599-606. 
114 
29. Fernandez, P.C., Frank, S.R.，Wang, L., Schroeder, M.，Liu, S., Greene, J., Cocito, A. 
and Amati, B. (2003) Genomic targets of the human c-Myc protein. Genes Dev. 17(9): 
1115-29. 
30. Sigal, A. and Rotter, V. (2000) Oncogenic mutations of the p53 tumor suppressor: the 
demons of the guardian of the genome. Cancer Res. 60: 6788-93. 
31. El-Shanawani, F.M., Abdel-Hadi，A.A., Abu Zikri, N.B., Ismail, A., El-Ansary, M. and 
El-Raai, A. (2006) Clinical significance of aflatoxin, mutant P53 gene and sIL-2 receptor 
in liver cirrhosis and hepatocellular carcinoma. J. Egy. Soc. ParasitoL 36(1): 221-39. 
32. Lleonart, M.E., Kirk, G.D., Villar, S.，Lesi，O.A., Dasgupta, A., Goedert，J.J., Mendy, M., 
Hollstein, M.C., Montesano, R., Groopman，J.D., Hainaut, P. and Friesen, M.D. (2005) 
Quantitative analysis of plasma TP53 249-Ser-mutated DNA by electrospray ionization 
mass spectrometry. Cancer Epid. Biom. Prev. 14(12): 2956-62. 
33. Jackson, P.E.，Kuang, S.Y.，Wang, J.B., Strickland, P.T., Munoz, A.，Kensler, T.W., Qian, 
G.S. and Groopman, J.D. (2003) Prospective detection of codon 249 mutations in plasma 
of hepatocellular carcinoma patients. Carcinogenesis. 24(10): 1657-63. 
34. Ndububa, D.A., Yakicier，C.M.’ Ojo, O.S.，Adeodu, O.O., Rotimi，O.，Ogunbiyi, O. and 
Ozturk, M. (2001) P53 codon 249 mutation in hepatocellular carcinomas from Nigeria. 
Afr. J. Med. Med. Sci. 30(1-2): 125-7. 
35. Turner, P.C., Sylla, A.，Kuang, S.Y., Marchant, CL . , Diallo, M.S., Hall, A.J.，Groopman, 
J.D. and Wild, C.P. (2005) Absence of TP53 codon 249 mutations in young Guinean 
children with high aflatoxin exposure. Cancer Epid. Biom. Prev. 14(8): 2053-5. 
36. El-Kafrawy, S.A., Abdel-Hamid, M., El-Daly, M.，Nada，O.，Ismail, A., Ezzat, S., Abdel-
Latif, S., Abdel-Hamid, A., Shields, P.G. and Loffredo, C. (2005) P53 mutations in 
hepatocellular carcinoma patients in Egypt. Int. J. Hyg. Environ. Health. 208(4): 263-70. 
37. Kuang, S.Y., Lekawanvijit, S., Maneekarn, N.，Thongsawat, S., Brodovicz，K., Nelson, K. 
and Groopman, J.D. (2005) Hepatitis B 1762T/1764A mutations, hepatitis C infection, 
and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epid. 
Biom. Prev. 14(2): 380-4. 
38. Cadwell, C. and Zambetti, G.P. (2001) The effects of wild-type p53 tumor suppressor 
activity and mutant p53 gain-of-function on cell growth. Gene 277: 15-30. 
39. Linda, J.K. and Prives，C. (1996) p53: puzzle and paradigm. Genes & Dev. 10: 1054-72. 
40. Ashcroft, M. and Vousden, K.H. (1999) Regulation of p53 stability. Oncogene. 18: 7637-
43. 
41. Chen, J., Jackson, P. K., Kirschner, M.W. and Dutta, A. (1995) Separate domains of p21 
involved in the inhibition o fCdk kinase and PCNA. Nature. 374:386-8. 
115 
42. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. and Elledge, S.J. (1993) The p21 
Cdk-interacting protein Cipl is a potent inhibitor of GI cyclin-dependent kinases. Cell. 
75: 805-816. 
43. Flores-Rozas, H.，Kelman, Z., Dean F.B., Pan，Z.Q., Harper, J.W., Elledge, S.J., 
O'Donnell, M. and Hurwitz, J. (1994) Proc Natl Acad Sci USA. 91(18): 8655-9. 
44. Takahashi, T., et al. (1997) Detection of proliferating cell nuclear antigen (PCNA) in 
peripheral blood mononuclear cells and sera of patients with malignant lymphoma. Leuk 
Lymphoma. 28(1-2): 113-25. 
45. Kawahira, K. (1999) Immunohistochemical staining of proliferating cell nuclear antigen 
(PCNA) in malignant and nonmalignant skin diseases. Arch Dermatol Res. 291(7-8): 
413-8. 
46. loachim，E., et al. (1999) Altered patterns of retinoblastoma gene product expression in 
benign, premalignant and malignant epithelium of the larynx: an immunohistochemical 
study including correlation with p53, bcl-2 and proliferating indices. Anticancer Res. 
19(lA):541-5 
47. Horiguchi, J., et al. (1998) Long-term prognostic value of PCNA labeling index in 
primary operable breast cancer. Oncol Rep. 5(3): 641-4. 
48. Danial, N. N. and Korsmeyer, S. J. (2004) Cell death: critical control points. Cell. 116: 
205-219. 
49. Fridman, J. S. and Lowe, S. W. (2003) Control of apoptosis by p53. Oncogene 22: 
9030-40. 
50. Zamzami, N.，Brenner, C., Marzo, I., Susin, S.A. and Kroemer, G. (1998) Subcellular 
and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene. 16: 2265-82. 
51. Bakhshi, A. et al. (1985) Cloning the chromosomal breakpoint of t(14;18) human 
lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 
18. Cell 41: 899-906. 
52. Yunis, J.J., Oken, M., Kaplan, M.E., et al. (1982) Distinctive chromosomal abnormalities 
in histology, subtypes of non-Hodgkin's lymphomas. N. Engl. J. Med. 307: 1231-6. 
53. Tsujimoto, Y. and Croce C.M. (1986) Analysis of the structure, transcripts, and protein 
products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. 
USA. 83: 5214-5218. 
54. Yang, J., Liu, X., Bhalla, K., Kim, C.N., Ibrado, A.M., Cai, J., Peng, T.I., Jones, D.P. and 
Wang, X. (1997) Prevention of apoptosis by Bcl-2: Release of cytochrome c from 
mitochondria blocked. Science. 275: 1129-32. 
116 
55. Hockenberry，D., Nunez, G., Milliman, C.，Schreiber, R. D. and Korsmeyer，S. J. (1990) 
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. 
Nature. 348: 334-336. 
56. Desoize, B. (1994) Anticancer drug resistance and inhibition of apoptosis. Anticancer 
Res. 14: 2291-2294. ^ 
57. Zamzani, N., Brenner, C., Marzo, I., Susan, S.A. and Kroemer, G. (1998) Subcellular and 
submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene. 16: 2265-82. 
58. Miyashita, T. and Reed, J.C. (1995) Tumor suppressor p53 is a direct transcriptional 
activator of the human bax gene. Cell. 80: 293-299. 
59. Miyashita, T., Krajewski, S.，Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A.， 
Hoffman, B. and Reed, J. C. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax 
gene expression in vitro and in vivo. Oncogene. 9: 1799-1805. 
60. Ludwig, R.L., Bates, S. and Vousden, K.H. (1996) Differential activation of target 
cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell Biol 
16(9): 4952-60. 
61. Wolter, K.G., Hsu, Y.T., Smith, CL., Nechushtan, A., Xi, X.G. and Youle, R.J. (1997) 
Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 139(5): 
1281-92. 
62. Vousden, K.H. (2000) p53: death star. Cell 103:691-4. 
63. Maki, C. G., Huibregtse, J. M. and Howley, P. M. (1996) In vivo ubiquitination and 
proteasome-mediated degradation of p53. Cancer Res. 56: 2649-54. 
64. Honda, R., Tanaka, H. and Yasuda, H. (1997) Oncoprotein MDM2 is a ubiquitin ligase 
E3 for tumor suppressor p53. FEES Lett. 420: 25-27. 
65. Tao, W. and Levine, A丄.(1999) Nucleocytoplasmic shuttling of oncoprotein Hdm2 is 
required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA 96: 3077-80. 
66. Jones, S.N., Roe, A.E., Donehower, L.A. and Bradley, A. (1995) Rescue of embryonic 
lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-8. 
67. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. and Weissman, A. M. 
(2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and 
p 5 3 . / . Biol. Chem. 275: 8945-51. 
68. Zhang, Z., Wang, H.，Li, M.，Agrawal, S., Chen, X. and Zhang, R. (2004) Mdm2 is a 
Negative Regulator of independent of p53. J.Biol. Chem. 279(16): 16000-6. 
117 
69. Power, C., Sinha, S.，Webber, C., Manson, M.M. and Neal, G.E. (1987) Transformation 
related to expression of glutathione S-transferase P in rat liver cells. Carcinogenesis 
8:797. 
70. Maugart-Loubootin, C., Charrier, J., Sagin, C., Cuilliere, P., Martin, S., Menegalli, D.， 
Lajat, Y., Resche, F. and Ali-Osman, F. (1996) Correlation between glutathione S-
transferases (GST) Pi expression in human astrocytomas determined by RT-PCR and 
histological grade. Proc Annu Meet Am Assoc Cancer Res. 37: A2305. 
71. Sato, K., Satoh, K.，Tsuchida, S., Hatayama，I., Shen, H.，Yokoyama, Y., Yamada, Y. 
and Tamai, K. (1992) Specific expression of glutathione S-transferase Pi forms in 
(Pre)neoplastic tissues - their properties and functions. Tohoku J Exp Med. 168: 97-103. 
72. LaDue, J.S. and Wroblewski, F. (1956) Serum glutamic pyruvic transaminase SGP-T in 
hepatic disease: a preliminary report. Ann Intern Med. 45(5): 801-11. 
73. Wiart, C., Kumar, K.，Yusof, M.Y., Hamimah, H.，Fauzi, Z.M. and Sulaiman, M. (2005) 
Antiviral properties of ent-labdene diterpenes of Andrographis paniculata nees, inhibitors 
of herpes simplex virus type 1. Phytother Res. 19(12): 1069-70. 
74. Reyes, B.A.，Bautista, N.D., Tanquilut, N.C., Anunciado, R.V., Leung, A.B., Sanchez, 
G.C., Magtoto, R.L., Castronuevo, P., Tsukamura, H. and Maeda, K.I. (2006) Anti-
diabetic potentials of Momordica charantia and Andrographis paniculata and their effects 
on estrous cyclicity of alloxan-induced diabetic rats. J. Ethnopharmacol. 105(1-2): 196-
200. 
75. Kumar, R.A., Sridevi, K.，Kumar, N.V., Nanduri, S. and Rajagopal, S. (2004) Anticancer 
and immunostimulatory compounds from Andrographis paniculata. J. Ethnopharmacol. 
92(2-3): 291-5. 
76. Panossian, A., Hovhannisyan, A., Mamikonyan，G., Abrahamian, H., Hambardzumyan, 
E., Gabrielian, E.，Goukasova, G.，Wikman, G. and Wagner, H. (2000) Pharmacokinetic 
and oral availability of andrographolide from Andrographis paniculata fixed combination 
Kan Jang in rats and human. Phytomed. 7(5): 351-64. 
77. Rajagopal, S., Kumar, R.A., Deevi, D.S., Satyanarayana, C. and Rajapopalan R. (2003) 
Andrographolide, a potential cancer therapeutic agent isolated from Andrographis 
paniculata. J. Exp. Ther. Oncol. 3(3): 147-58. 
78. Shen, Y.C., Chen, C.F. and Chiou W.F. (2002) Andrographolide prevents oxygen radical 
production by human neutrophils: possible mechanism(s) involved in its anti-
inflammatory effect. Br. J. Pharmacol 135(2): 399-406. 
79. Visen, P.K., Shukla, B., Patnaik, G.K. and Dhawan, B.N. (1993) Andrographolide 
protects rat hepatocytes against paracetamol-induced damage. J. Ethnopharmacol. 40(2): 
131-6. 
80. Iruretagoyena, M.I., Hermoso, M., Sepulveda, S.E., Lezana, J.P., Bronfman, M., 
Gutierrez, M.A., Jacobelli, S.H. and Kalergis, A.M. (2006) Inhibition of nuclear factor-
118 
kappa B enhances the capacity of immature dendritic cells to induce antigen-specific 
tolerance in experimental autoimmune encephalomyelitis. J. Pharmacol. Exp. Ther. 318: 
59-67. 
81. Tsai，H.R., Yang, L.M., Tsai，W.J. and Chiou, W.F. (2004) Andrographolide acts through 
inhibition of ERKl/2 and Akt phosphorylation to suppress chemotactic migration. Eur. J. 
Pharmacol 498(1-3): 45-52. 
82. Qin, L.H., Kong, L., Shi, G. J., Wang, Z.T. and Ge, B.X. (2006) Andrographolide inhibits 
the production of TNF-alpha and interleukin-12 in lipopolysaccharide-stimulated 
macrophages: role of mitogen-activated protein kinases. Biol. Pharm. Bull. 29(2): 220-4. 
83. Madav, H.C., Tripathi, T. and Mishra, S.K. (1995) Analgesic, antipyretic, and 
antiulcerogenic effects of andrographolide. Indian J. Pharm. Sci. 57(3): 121-25. 
84. Matsuda, T., Kuroyanagi, M., Sugiyama, S., Umehara, K., Ueno, A. and Nishi, K. (1994) 
Cell differentiation-inducing diterpenes from Andrographis paniculata nees. Chem 
Pharm Bull 42(6): 1216-25. 
85. Kapil, A., Koul, LB., Banerjee, S.K. and Gupta, B.D. (1993) Antihepatotoxic effects of 
major diterpenoid constituents of Andrographis paniculata. Biochem. Pharmacol. 46(1): 
182-5. 
86. Wyllie, A.H. (1980) Glucocorticoid-induced thymocyte apoptosis is associated with 
endogenous endonuclease activation. Nature. 284: 555-6. 
87. Norbury, C. and Nurse, P. (1992) Animal cell cycles and their control. Ann. Rev. of 
Biochem. 61: 441-70. 
88. Fearon, E.R. (1997) Human cancer syndromes: Clues to the origin and nature of cancer. 
Science. 278: 1043-50. 
89. Rao, P.N. (1980) The molecular basis of drug-induced G2 arrest in mammalian cells. Mol. 
Cell Biochem. 29(1): 47-57. 
90. Quelle, D.E., Ashmun, R.A.，Shurtleff, S.A., Kato, J.Y., Bar-Sagi, D., Roussel, M.F., and 
Sherr, C J. (1993). Overexpression of mouse D-type cyclins accelerates GI phase in 
rodent flbrolasts. Genes Dev. 7: 1559-1571. 
91. Lee, R.J.，Albanese, C.，Stenger, R.J., Watanabe, G., Inghirami, G., Haines, G.K., 
Webster, M.，Muller, W.J., Brugge, J.S., Davis, R.J. and Pestell, R.G. (1999). 60(v-src) 
induction of cyclin Dl requires collaborative interactions between the extracellular 
signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response 
element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in 
breast cancer cells. J. Biol. Chem. 274: 7341-50. 
92. Arber, N., Hibshoosh, H., Moss, S.F., Sutter, T., Zhang, Y.，Begg, M.，Wang, S., 
Weinstein, LB. and Holt, P.R. (1996). Increased expression of cyclin D1 is an early event 
in multistage colorectal carcinogenesis. Gastroenterology 110: 669-74. 
119 
93. Dyson, N. (1998) The regulation of E2F by pRB-family proteins. Genes Dev. 12; 2245-
62. 
94. Clarke, A. R., Maandag, E.R.，VanRoon, M., Van der Lugt, N.M.T., Vander Valk，M., 
Hooper, M.L., Bems, A., Te, H. and Riele. (1992) Requirement for a functional Rb-1 
gene in murine development. Nature (London) 359: 328-30. 
95. Wyllie, A.H. (1992) Apoptosis and the regulation of cell numbers in normal and 
neoplastic tissues: an overview. Cancer Metastasis Rev. 11: 95-103. 
96. Jin, Z. and El-Deiry, W.S. (2005) Overview of cell death signaling pathways. Cancer 
Biol. Ther. 4(2): 139-63. 
97. Cho, S.G. and Choi, E.J. (2002) Apoptotic signaling pathways: caspases and stress-
activated protein kinases. J. Biochem. Mol. Biol. 35(1): 24-7. 
98. Panaretakis, P., Pokrovskaja, K., Shoshan, M.C. and Grander, D. (2002) Activation of 
Bak, Bax and BH3-only Proteins in the Apoptotic Response to Doxorubicin. J. Biol 
Chem. 277(46): 44317-26. 
99. Agarwal, ML., Taylor, W.R., Chernov, M.V., Chernova, O.B. and Stark, G.R. (1998) 
The p53 network. J Biol Chem. 273: 1-4. 
100. Schwarz, M.，Buchmann, A. and Bock, K.W. (1995) Role of cell proliferation at early 
stages of hepatocarcinogenesis. Toxicol. Lett. 82-83. 
101. Tomasi, C., Laconi, E., Laconi, S.，Greco, M., Sarma, D.S. and Pani, P. (1999) Effect of 
fasting/refeeding on the incidence of chemically induced hepatocellular carcinoma in the 
rat. Carcinogenesis 20: 1979-83. 
102. Farber, E. and Sarma, D.S.R. (1987) Hepatocarcinogenesis: a dynamic cellular 
perspective. Lab. Inves. 56: 4-21. 
103. Columbano, A., Ledda-Columbano, G.M., Curto, M.，Ennas, G.M. Coni, P., Sarma, 
D.S.R. and Pani, P. (1990) Cell proliferation and promotion of rat liver carcinogenesis: 
different effect of hepatic regeneration and mitogen-induced hyperplasia on the 
development of enzyme altered foci. Carcinogenesis. 11: 771-776. 
104. Ogawa, K.，Solt, D.B., Farber, E. (1980) Phenotypic diversity as an early property of 
putative preneoplastic hepatocyte populations in liver carcinogenesis. Cancer Res. 40: 
725-33. 
105. Roomi, M. W., Columbano, A., Ledda-Columbano, G. M., and Sarma, D. S. R. (1986) 
Lead nitrate induces certain biochemical properties characteristic of hepatocyte nodules. 
Carcinogenesis. 7: 1643-6. 
120 
106. Power, C.，Sinha, S., Webber, C., Manson, M.M. and Neal, G.E. (1987) Transformation 
related to expression of glutathione S-transferase P in rat liver cells. Carcinogenesis. 8: 
797. 
107. Vadenberghe, Y., Morel, F., Foriers, A., Ketterer, B., Vercruysee, A., Guillonzo, A. and 
Rogiers, V. (1989) Effect of Phenobarbital on the expression of glutathione S-transferase 
isozyme in cultured rat hepatocytes. FEES Lett. 251: 59. 
108. Clawson, G.A. (1989) Mechanisms of carbon tetrachloride hepatoxicity. Path. 
Immunopathol Res. 8: 104-12. 
109. Recknagel, R.O., Glende, E.A., Dolak, J.A. and Waller, R丄.(1989) Mechanisms of 
carbon tetrachloride toxicity. Pharmacol. Ther. 43: 139-54. 
110. Schulte-Hermann, R. (1979). Adaptive liver growth induced by xenobiotic compounds: 
Its nature and mechanism. Archives of Toxicology 2: 113-24. 
111. McGhee, J.O'D. and Patrick, R.S. (1969) The synthesis of sulphated mucopolysaccharide 
in mouse liver following carbon tetrachloride injury. I. Autoradiographic studies. Br. J. 
Exp. Pathol. 50: 521-26. 
121 

C U H K L i b r a r i e s 
004439913 
